

# AMBER N. BRACY

---

## PROFESSIONAL SUMMARY

---

### **Expert in: Financial Reporting ~ Strategic Budgeting ~ Implementing Marketing Strategies**

Strategic problem solver who envisions productive solutions and implements them into daily tasks. Self-motivated leader who is experienced in managing large, mid-size and small teams to ensure that the target goals are clear & precise, so that all parties remain focused and effective. Organized professional who constantly keeps the best interest of both the consumer, companies & stake holder's interest a main priority. A visionary with the social skills to restore the American heritage & vision by achieving the simplicity of its intended textual form as it was written.

### **CORE COMPETENCIES**

Relationship Building by Breaking Through Social & Economical Lines ~ Calculating daily exchange rates & currencies ~ Maximizing Quantitative & Qualitative Available Assets ~ AP & AR Task ~ Analyzing Market Trends & Forecasting Upcoming Changes ~ Predictive Analytics ~ Collections & Payroll ~ Budget Planning & Marketing Strategies ~ Detailed Expense Reporting Cloud Service ~ Managing Multiple Domestic & International Billing Systems ~ VPN ~ VoIP ~ Cost Reduction ~ Team Development

---

## EDUCATION CREDENTIALS

---

**Bachelor's Degree in Political Science with a Concentration in Public Administration & International Affairs**  
**Graduated with cumulative GPA of 3.8**  
Kennesaw State University, Kennesaw, Georgia

---

## PROFESSIONAL AWARDS & CERTIFICATES

---

- **Creator of '#123 Set Them Free Campaign'; a tool designed to assist in eradicating human trafficking**
- **Achieved Six Sigma Green Belt Certificate**
- **President Volunteer Service Award received, 2015-2018**
- **Board Member of AT&T Global Diversity & Inclusion Leadership Team**
- **Recipient of the AT&T Finance Wall of Stars Recognition Award**

---

## COMMUNITY SERVICE & PARTNERSHIPS

---

- **Member of Victory World Church, Norcross & Buford Georgia**
- **Volunteer, C.A.S.A (Court Appointed Special Advocate) Forsyth Georgia**
- **Volunteer, Actively Coached multiple YMCA Youth Soccer Teams, Alpharetta**
- **Advocate, Free the Slaves, International NPO**
- **PAC (Political Actions Committee) Member with AT&T**

**➤ Advocate, Not for Sale in Atlanta, Georgia**

Educated the public and local educational institutes on the human trafficking crisis worldwide. Assisted in mobilizing an international grassroots social movement that effectively combats human trafficking and modern-day slavery through "*Smart Activism*".

**Key Achievements**

- Contributed to the organization of the Student Abolitionist Movement (SAM), which is a network of students fighting to end modern-day slavery. It is designed to help collaborate students and their ideas in efforts to combat human trafficking in solidarity. SAM provides students with key programs and resources to take action, educate, and advocate for the end of the global slave trade.
- Published news articles that encouraged communities to become more aware and involved in cause

---

**RECENT CAREER TRACK**

---

**Senior Finance Billing Analyst, Finance Department in Atlanta Georgia, 2014 – Current**

Successfully reconciled various billing issues within both external & internal billing systems, while partnering with IT and Cash Ops teams to properly bring attention to the financial matters that had been carried on for multiple cycles. Successfully delegated job task to team members to ensure all areas of business were completed in the event of any team member absences. Monthly provided a high-level summary outlining key details of matters that occurred; the report included items that needed further attention. Developed and updated tools, queries, and reports in conjunction with ongoing business changes & mergers.

**Key Achievements**

- Currently leading ERG (Employee Resource Group) as the appointed National Chair to Eradicate Human Trafficking; collaborating with various resources to bridge the gap among global corporate companies, community outreach organizations and law enforcement agencies to effectively combat modern day slavery & human trafficking.
- Successfully worked with domestic & international team members to allow FBO ability to send in foreign payment approvals electronically, compared to the previous task which included physically shipping management approvals to the assigned locations. Correctly processed AP and AR transactions accurately within (3) work days for over (154) wholesale accounts.
- Collaborated with multiple groups on a highly time sensitive project (*PID 304043 - Syniverse SMS Aggregators Collection Project*); which allowed AT&T to collect millions in revenue for SMS charges accrued on multiple off portal aggregator accounts.
- Diligently trained team members to properly complete high important FBO job task; which included weekly training sessions to review the job task at a pace to ensure the opportunity to absorb the information, ask questions and ultimately exercise the new obtained skill.
- Collaborated with other contacts to ensure that the FBO projects are archived correctly in Archer and on the AT&T P-8 database; task needed for a positive internal or external audit & to ensure that we are compliant with the Sarbanes Oxley laws.

**Revenue Assurance Analyst, AT&T Mobility in Atlanta Georgia, 2012 – 2014**

Completed relatively complex revenue related audits, issue research and resolution, complex and strategic project support, analytical assignments, and designs and prepares audits and reports. Designed & Implemented Proactive and new Risk Based audits. Implemented and tracked preventative revenue findings and new reporting for the National Revenue Assurance Team. Completed validations on all automated call tests performed by Message Processing Teams as required by SOX compliance guidelines. Ensured that the validations included reporting and tracking of all billing issues. Focused on current audit roles to enhance test scenario's and/or quantify issues discovered. Participated in adhoc testing for successful launches of new products and services for the Product Development teams as requested. Created more efficient reporting tools to better report any issues discovered to the project managers, and ensured they followed until a resolution was completed.

**Key Achievements**

- Completed validations for (141) SOX audits; all audits were completed within the required SLA guidelines and following company procedures; led FBO group to achieve surpassing audit ratings
- Created a validation tool that simplified multiple 'Big Data' search engines to better report & track years of extensive records from consumer usages over various rate plans & markets.
- Successfully assisted in HLR/ MSISDN job tasks; confirming whether the accounts are active in Snooper & Telegence if not deleting them and documenting the status
- Researched records pertaining to the revenue stream and collaborated with current process owners to take corrective action that better ensured a timely and accurate billing methods

**Community Director, Wilkinson Real Estate Advisors Atlanta, Georgia, 2009 – 2012**

Focusing on creating a team atmosphere that promotes goals which are directed towards achieving high occupancy levels. Constantly staying informed of market conditions, competitive pricing, and utilizing appropriate resources. Establish and achieve financial goals by effectively qualifying prospective residents and verifying applications. Diligently working to assist both the Regional Manager & investors, as needed in long-range planning, communications, and other tasks, while keeping Bell philosophies as a focal point.

**Key Achievements**

- Successfully thrived to maintain and improve the value of the community's features within the scope of its inherent design.
- Promoted positive, proactive resident relations by demonstrating a "firm, fair, and consistent" manner in all resident contacts, keeping in mind the current economical recession that effected the community & social impacts of the housing decisions.

---

**PERSONAL ATTRIBUTES**

---

Multi-tasked ~ Self Motivated ~ Highly Responsible ~ Well Organized ~ Very Reliable ~ 80+ wpm ~ Great Communication Skills ~ Extraordinary Leadership Abilities ~ Seasoned Management and Accounting experience ~ Personable & Approachable ~ Highly Disciplined ~ Punctual ~ Attention to Detail to avoid future complications ~ Honest ~ Holds integrity at a high level

# Casey Thomas Cato

## Overview

Present markets dictate that today's IT professional not only require a solid foundation in technical expertise, but also a fundamental understanding of the challenges facing today's business managers. The task is to bridge these two solitudes by providing solutions based on a thorough understanding of the problem.

## Professional Profile

A highly accomplished professional with over twenty years of progressive, successful achievement through applying a hands-on, team oriented approach in areas including project management, business functional process, resource management, information technology, and the software development lifecycle. Positioned to provide expertise in technology and non-technology related initiatives and to be afforded the opportunity to learn new skills and reinforce developed ones in a dynamic and challenging environment.

- 20+ years Data integration Experience
- 20+ years Healthcare Experience
- 15+ years Project Management Experience
- 15+ years HL7/EDI Developer Experience
- 15+ years Multi Interface Engine Experience
- 15+ years QA, automated test scripting, HL7, HCPCS, ICD 9

## Highlights of Professional Experience

### Northrop Grumman Corporation - Atlanta, Georgia

07/17 to Present

Technology Manager – Contractor to Centers for Disease Control (CDC)

Provided leadership for the Microsoft (Northrop Grumman) team at the CDC (about 12 staff) for various software development projects within the CDC's National Center for HIV, Hepatitis, STD, Tuberculosis Prevention (NCHHSTP) division of Informatics. Managed and directed staff and projects embracing the CDC's migration from on premise Microsoft technologies to cloud based Azure based technologies. Many projects our teams worked upon were NCHHSTP wide (1500+ staff) to agency-wide initiatives throughout the CDC and other entities such as HHS (Health and Human Services) and the WHO (World Health Organization).

Primary Technologies/Skills: project management, business analysis, software development & implementation, Microsoft SQL Server, Microsoft Power BI, Microsoft Dynamics 365, Microsoft SharePoint, data analytics, Informatics

### Children's Healthcare of Atlanta - Atlanta, Georgia

08/12 to 07/17

Project Manager - IS&T

Provided leadership for Children's Healthcare of Atlanta (Egleston, Scottish Rite and Hughes Spalding hospitals) in demonstrating superior customer service and support of business specific projects, initiatives, hardware and application requirements. Managed various teams of IT professionals that implement solutions and provide technical and functional support of new/existing software applications and hardware platforms. Work with business groups to ensure operational stability and that applications meet the practical needs of the organization.

Primary Technologies/Skills: project management, business analysis, software development & implementation, Microsoft Exchange, Ascom, Cisco, video conferencing, wired/wireless networking, call center, data/tape backups, Norton Symantec, Microsoft Active Directory, Lawson, Chartmaxx, Epic, IBM PureFlex, HP UX, IBM AIX, patch management, IBM Endpoint Manager, Microsoft Sharepoint, Microsoft Project; Qlikview, Interface Engines, Corepoint, Windows OS upgrades, EMC Data Domain/Avamar, EMC VNX/Isilon, Philips device integration, facility construction, cabling

### Engage Inc. - Atlanta, Georgia

02/10 to 08/12

Lead Health Practice Project Manager and Business Analyst – Engage Development  
Quality Assurance Department Manager – Engage Development

Manager of the Quality Assurance department. Developed processes and initiatives for Engage Agile/SCRUM development processes. Managed projects and initiatives, and conducted business analysis with regards to all healthcare related accounts, including the complete development of a healthcare scheduling and billing solution with associated integration to downstream third party systems. Developed technical and user documentation, as well as, customer training/education materials, including training videos and real time online seminars. A Microsoft Certified Gold Partner and Professional.



Recently finished Project Management of and Business Analysis of Aston Martin Lagonda's development of their website, including eCommerce, web analytics, social media, streaming video, content management system and gaming/badging layer. This was Engage's largest web deployment to date.

Primary Technologies/Skills: project management, QA, business analysis, software product development & implementation, technical writing, Scrum/Agile, Microsoft Dynamics CRM, Microsoft SQL Server, web content management system, web analytics, javascript programming, healthcare scheduling and billing, ICD 9/10, HCPCS, HL7, Javascript

### **McKesson Corporation - Alpharetta, Georgia**

**02/08 to 02/10**

HzERM (Horizon Enterprise Revenue Management) Senior Quality Assurance Analyst – HzERM QA Integration

Utilizing Mercury Quality Center, wrote and executed various types of test cases, both manual as well as automated, with a focus upon HzERM integration and interfaces. Analyzed HL7 (Health Level 7) data for inbound and outbound interfaces per customer specifications and HL7 guidelines. Conducted testing of interfaces within company configured test environments, as well as customer test environments, including development and configuration of interfaces for compatibility with third party downstream hospital applications and interface engines. Provided onsite customer assistance for product go lives. Coordinated some administrative tasks for group.

Primary Technologies/Skills: QA, automated test scripting, software product development & implementation, HL7, HCPCS, ICD 9, interface engines, Java, implementation specialist

### **McKesson Corporation - Alpharetta, Georgia**

**09/06 to 02/08**

STAR Services Application Programmer Analyst – STAR Services Integration

Project managed, coded and implemented STAR HL7 interfaces for various McKesson and non-McKesson hospital products. Customized interfaces per customer work orders for compatibility with various third party hospital applications and interface engines. Coordinated the testing of customizations and implementations for customers within development, QA and production environments. Supported implementations on on-call basis 24/7.

Primary Technologies/Skills: Software product development, MUMPS, Visual Basic, HL7, interface engines, ICD 9, HCPCS

### **Navicure Inc - Duluth, Georgia**

**2/06 to 09/06**

Senior EDI Implementation and Software Engineer

Company responsibilities include Project Management, Development, QA, and Implementation into Production of new EDI interfaces to insurance payers for customers/providers. Additionally, analyzing ANSI X12 837, 277, 997, and 835 data both to and from payers. Coordinated with customer and third party vendors the project development of new EDI interfaces to new insurance payers.

Primary Technologies/Skills: Software product development, software interface & integration development, EDI X-12, Java, healthcare billing and claims, insurance providers; QA

### **Allscripts (Eclipsys) Corporation - Atlanta, Georgia**

**11/04 to 2/06**

Enterprise Integration Configuration Manager – eLink/Sunrise Integration Module  
Senior Test Engineer

Setup and maintain an integrated test environment for QA of the Eclipsys products eLink and SIM (Sunrise Integration Module), including the installation and configuration management of all Eclipsys products (Sunrise Clinical Manager, Sunrise Medication Management, Sunrise Record Manager, Access Manager, Patient Financial Management, etc.). QA of new eLink and SIM releases, including the integration into other products via HL7 messages. Programming of automated testing scripts in Mercury Quick Test Professional and execution through Mercury Test Director. QA of Pocket PC versions of eLink and SIM.

Primary Technologies/Skills: Software product development, HL7, interface engines; Mercury (HP) Test Center

### **McKesson Corporation - Alpharetta, Georgia**

**3/01 to 11/04**

Interface Analyst – Horizon Meds Manager (Pharmacy)  
STAR Team Leader for Medical Records, Order Management, Patient Processing and Integration Teams  
STAR Interface Specialist- Integration Team

Managed Medical Records, Order Management, Patient Processing and Integration teams within STAR HIS. Project management of development projects for these teams. Utilized Maxi-MUMPS and Visual Basic in programming efforts, which included HL7, X-12, HIPAA and Equifax related projects.

Primary Technologies/Skills: Software product development, HL7, interfaces engines; healthcare IT; programming; MUMPS; Visual Basic; EDI X-12

## **Allscripts (Eclipsys) Corporation – Marietta, Georgia**

**3/99 to 9/99**

Technical Consultant

Authored SQL database interfaces using TLink product suite for corporate clients. Additionally, authored TView applications for deployment within a Web interactive environment. Assisted in the development of and testing of project implementation.

Primary Technologies/Skills: HL7, interface engines, SQL Server; healthcare IT

## **Application Interfacing Corporation (AIC) – Duluth, Georgia**

**2/98 to 3/99 and 9/99 to 3/01**

Systems Engineer

Assembled and authored HL7 compliant technical documents for various medical information system interfaces. Programmed HL7 compliant application interfaces for medical information system clients as well as integration with customer interface engines. Aided in the installation and configuration of corporation local area network and wide area network. Installed and configured corporation Windows NT LAN and workstations. Aided in daily office management procedures.

Primary Technologies/Skills: project management, IBM Websphere, HL7, interface engines, C/C##, Perl, Visual Basic

## **Gwinnett County Planning and Development – Lawrenceville, Georgia**

**9/92 to 2/98**

Principal Planner and Geographic Information Systems Liaison, Planning Data Services Division

Senior Planner, Planning Data Services Division

Senior Planner, Long Range Planning Division

Managed Planning Division staff in the development of the Planning Division's responsibilities for the county's Geographic Information System (GIS). Utilized project management skills to develop and maintain a Planning Division land use, existing land use, area policy, long range road classification, zoning and various other specialized drawing and data layers for use within the county's Geographic Information System. Engineered specialized program applications for the county's Geographic Information System. Assisted in the development and maintenance of manual and computerized databases, including the GIS database. Provided PC hardware and software technical support to department staff. Assisted in the coordination and composition of the annual updates to Gwinnett's Comprehensive Plan. Developed and conducted presentations to the Planning Commission, Board of Commissioners, other departments and the public at large. Researched and tabulated data to produce technical reports, brochures and maps for county and public use addressing land use, transportation, environmental and other planning concerns.

## **IBM Corporation – Marietta, Georgia**

**5/92 to 9/92**

Technical Support Representative, IBM PS/1 Personal Computers

IBM PS/1 Personal Computer support implemented through various on-line services and via the telephone. Conducted various problem-solving techniques with computer software programs and hardware peripherals in order to answer a variety of IBM PS/1 computer questions for customers. Constructed "Help" files for customers for Frequently Asked Questions, PC maintenance and installation topics.

## **City of Alpharetta – Alpharetta, Georgia**

**Summer 1991**

Georgia State University Internship, City Planning Department

Created land use profiles for amendment to official city ordinance. Identified and investigated legal parcels by land use for potential city annexation. Researched and updated the official land use and zoning maps. Reviewed and evaluated engineering plans for potential development.

## **IBM Corporation – Marietta, Georgia**

**Co-Op while attending classes (Summer 1986 to 1992)**

Technical Writer, Integrated Systems Solution Corporation – Selected International Accounts

Developed and edited custom Script files. Authored technical guides for internal and customer use. Aided in the development of internal and customer technical and marketing presentations.

## **Education**

### **Georgia State University**

Master of Science in Public and Urban Affairs - 1992

### **Related Coursework**

Community Organizing, Demographics, Government and Non-Profit Planning, Measurements and Statistics, Public-Private Partnerships

### **University of Georgia**

Bachelor of Arts in Geography - 1990

### **Related Coursework**

Economics, Geographic Information Systems, Graphic Cartography, Information Processing and Microcomputers, Money and Banking, Philosophy, Spanish

### **Honors, Awards and Leadership**

Dean's List, Gamma Theta Upsilon – National Geography Honor Society, Geography Club

### **Gwinnett Technical Institute**

Associate in Applied Technology in Computer Programming Technology – In Progress

### **Related Coursework**

Accounting, "C", Computer Installation and Maintenance, Microsoft Visual Basic, Networking Concepts, Operating Systems, Program Design and Development, TCP/IP, Installing and Administering Windows NT Server 4.0, Installing and Administering Windows NT Workstation 4.0, Installing and Administering Windows NT Enterprise Server 4.0, Networking Essentials, Microsoft Internet Information Server

## **Certifications**

### **Microsoft Corporation**

Microsoft Certified Professional

Microsoft Certified Professional Plus Internet

Microsoft Certified Systems Engineer – currently obtaining

Implementing and Supporting Windows NT Server 4.0 (70-067) passed

Implementing and Supporting Windows NT Workstation 4.0 (70-073) passed

Implementing and Supporting Windows NT Server 4.0 in the Enterprise (70-068) passed

Networking Essentials (70-058)

Internetworking with Microsoft TCP/IP on Windows NT 4.0 (70-059)

Implementing and Supporting Microsoft Internet Information Server 4.0 (70-087)

CRM 4.0 Applications (MB2-632)

### **McKesson Corporation**

Horizon Web Solutions Technical Certification

Leadership Certification

### **Health Level Seven Organization**

HL7 Certified

### **PMP**

PMP Certification candidate – in progress ETA November 2016 (Project Management Academy boot camp)

## **Keywords**

Windows 2000, Windows XP, SQL, TLink, Mercator, Unix, OS/2, VMS, Visual Basic, HTML, JavaScript, IIS, Microsoft Internet Information Server, "C", Web Design/Development, Microsoft Office, Visual Source Safe, Seagate Backup Exec, PC Maintenance and Installation, Network Installation/Support, Communication Protocols, TCP/IP, Training, Multimedia, Application Development, Project Management, Manager, Technical Documentation, Resource Management, Infrastructure Implementation, Technical Management, Health Level Seven, HL7, STAR, MUMPS, EDI X-12, HIPAA, HBOCHI, eLink, SIM, SCM, SMM, Sunrise Clinical Manager, Sunrise Integration Module

# ***Diane Barton***

## ***Marketing Executive - Long-Time Georgia Resident, Family-Centric Community Leader***

- *Experienced change & communications strategist and writer*
  - *Built CX (customer experience) practice - Deep understanding of serving customers, constituents and communities*
  - *Ran multi-million dollar customer-facing technology projects*
  - *Managed high-performing teams*
- 

## **ENDEAVORS**

### ***Community Board Member & Development Volunteer***

#### ***Children's Healthcare of Atlanta: 1998 - Present***

Led campaign to name and endow Cardiac Intensive Care Unit. More than \$9 million raised to date.

### ***Board of Directors: Marketing & Development Committees***

#### ***Chattahoochee Nature Center: 2011 - Present***

Helping team expand mission of educating community about the watershed, conservation and sustainability with a special focus on marketing and communications.

## **EXPERIENCE**

### ***C3: 2013 – Present***

Consulting firm specializing in marketing and communications strategy, planning, and implementation designed to grow employee and customer loyalty while increasing revenue. Expertise includes aligning marketing function with an organization's strategic plan and goals, communications, change management, customer research, competitive analysis, customer touchpoint design, marketing, and success metrics implementation. Recent projects include change management and communications strategy and execution for a large cloud migration project, corporate rebranding and corporate website update.

### ***Vice President - Customer Experience / Marketing***

#### ***Cox Enterprises/Manheim: 2002 – 2013***

- Successfully built customer experience organization in an international, operations-driven corporation. Included introducing customer satisfaction metrics, process improvements, customer self-service, front-line employee empowerment, and a comprehensive change management program. Managed 60+ person call center.
- Managed relationship with Ford Motor Company, Manheim's largest customer. Responsible for strategic planning, contract negotiations, new product introductions, sales, and profitability analysis.
- Led 25+ person marketing organization for the global wholesale automobile auction and services division of Cox Enterprises, Inc. Included

internal and external communications, advertising, research, trade shows, delivering results, and meeting budget.

***Director - Marketing, Manager - Marketing***

***Cox Enterprises/Manheim: 1991 - 2002***

As the first member of the marketing communications organization for Manheim, responsibilities included creating strategy, branding, organizational alignment, hiring and managing agencies, and building the marketing communications department.

***Assistant Manager - Corporate Communications***

***Cox Enterprises: 1989 - 1991***

Handled all corporate communications needs for two divisions of Cox Enterprises. This included developing and implementing the strategy for internal and external communications, newsletters, annual reports, and leadership presentations.

***Marketing Writer***

***The Atlanta Journal-Constitution: 1987 - 1989***

Wrote and managed the production of sales collateral for the advertising sales team. Created and delivered research-driven presentations to clients.

For additional employment experience please see Diane Barton's LinkedIn profile. <http://www.linkedin.com/pub/diane-barton/35/a23/91>

## EDUCATION

---

***Emerson College***

Bachelor of Science - Mass Communications

***Toyota University***

Kaizen Certification

***Emory University - Goizueta Business School***

Certificate in Strategic Marketing

---

## EXTRAS

***Family***

Son graduated from UGA in 2019, Daughter graduates from Tulane University in 2020. Widowed in 2018 unexpectedly. Husband was an elementary school teacher in Sandy Springs. Life experience has uniquely prepared me to serve and represent the people of Georgia.



**EMORY UNIVERSITY SCHOOL OF MEDICINE  
STANDARD CURRICULUM VITAE**

Revised: September 1, 2019

**1. Name:** R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA

**2. Office Address:**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

**4. Citizenship:** USA

**5. Current Titles and Affiliations:**

a. Academic Appointments:

i. Primary Appointment:

Professor  
Department of Hematology and Medical Oncology  
Emory University School of Medicine  
Effective September 2019

ii. Secondary Appointment:

Professor  
Department of Pharmacology and Chemical Biology  
Emory University School of Medicine  
Effective September 2019

b. Clinical Appointment:

Director  
Phase I Clinical Trials Unit and Section  
Winship Cancer Institute of Emory University  
May 2007 – present

c. Other Administrative Appointment:

Chair  
Data Safety and Monitoring Committee  
Winship Cancer Institute of Emory University  
May 2016 – present

**6. Previous Academic and Professional Appointments:**

Clinical Assistant Professor  
University of North Carolina School of Pharmacy  
July 1997 – June 2005

Clinical Assistant Professor  
University of Georgia College of Pharmacy  
December 2005 – July 2006

Medical Science Liaison  
Alexion Pharmaceuticals, Inc.  
July 2006 – May 2007

Assistant Professor  
Department of Hematology and Medical Oncology  
Emory University School of Medicine  
May 2007 – September 2013

Associate Professor  
Department of Hematology and Medical Oncology  
Emory University School of Medicine  
September 2013 – September 2019

Associate Professor  
Department of Pharmacology  
Emory University School of Medicine  
February 2016 – present

**7. Previous Administrative and/or Clinical Appointments:**

Clinical Specialist  
Stem Cell Transplantation and Hematology/Oncology/Coagulation Consult Service  
University of North Carolina Hospitals  
July 1998 – June 2000

Senior Clinical Specialist  
Hematology/Oncology/Coagulation  
University of North Carolina Hospitals  
June 2000 – June 2005

Co-Director, Hematology/Oncology Specialty Residency  
University of North Carolina Hospitals and School of Pharmacy  
July 2001 – June 2005

Clinical Specialist in Hematology/Oncology  
Director, Hematology/Oncology Specialty Residency  
Georgia Cancer Center/Grady Health System  
July 2005 – June 2006

**8. Licensures/Boards:**

North Carolina Board of Pharmacy, issued June 1994  
Georgia Board of Pharmacy, issued June 2005

**9. Specialty Boards:**

Board Certified Pharmacotherapy Specialist, 1997 – 2011  
Board Certified Oncology Pharmacist, 2000 – present

**10. Education:**

BS with Honors, Pharmacy, University of North Carolina, Chapel Hill, 1989 – 1994  
PharmD, University of North Carolina, Chapel Hill, 1994 – 1996

## 11. Postgraduate Training:

Pharmacy Practice Resident (R237), University of Kentucky Medical Center and College of Pharmacy,  
Lexington, KY  
Director: Mick Hunt, MS  
July 1996 – June 1997

Hematology/Oncology Specialty Resident, University of North Carolina Hospitals and School of Pharmacy  
Chapel Hill, NC  
Director: Celeste Lindley, MS, PharmD, BCOP, FASHP, FCCP  
July 1997 – June 1998

## 12. Committee Memberships:

### a. National and International:

American College of Clinical Pharmacy (ACCP)  
Programming Committee 2001-2002  
Awards Committee 2004-2007

Hematology Oncology Pharmacy Association (HOPA)  
Education and Standards Committee 2005-2008  
Co-chair, Professional Affairs Committee 2008-2009  
Chair, Professional Affairs Committee 2009-2010  
President, 2010-2013  
Vice Chair, Research Committee 2013-2015  
Chair, Research Committee 2015-2017  
Committee Restructuring Task Force 2016  
Chair, External/Professional Affairs Committee 2017-2018  
Recognition Committee 2018-present

American Society of Health-System Pharmacists (ASHP)  
Chair, Special Interest Group on Emerging Sciences, 2013-2014

American Society of Clinical Oncology (ASCO)  
Advocacy Champion for Hill Day 2015-present  
Clinical Trials Eligibility Criteria Initiative: Organ Function 2015-2016  
ASCO University Pharmacology Representative 2015-2017  
Annual Meeting Programming Committee – Developmental Therapeutics 2017-present  
Roundtable on Addressing Financial Barriers to Clinical Trials Participation – Steering Group  
member 2017  
Biosimilars Brief Development 2017  
Research Hill Day participant 2017  
Cancer Research Committee  
Member 2017-present  
Chair 2019-2020  
Joint ASCO/FDA Workshop on Research Biopsies in Phase I Trials  
Speaker, organizing committee, 2018-present  
Building Consensus for a Clinical Trial Data Sharing Policy Among Oncology Journals  
Workshop  
Panelist 2018

American Society for Clinical Pharmacology and Therapeutics (ASCPT)  
Chair, Oncology Scientific Section 2014-2015

Alliance for Clinical Trials in Oncology



Member, Pharmacogenomics and Population Pharmacology Committee 2018-present

b. Regional:

North Carolina Association of Pharmacists (NCAP)  
Pharmacotherapy Advisory Committee, 2000-2004  
Acute Care Practice Forum, 2001-2005

Triangle College of Clinical Pharmacy (TCCP)  
President 2004-2005

c. Institutional:

Resident Advisory Committee, University of North Carolina Hospitals and School of Pharmacy  
1999-2005

Transfusion Committee, University of North Carolina Hospitals 1999-2005

Palliative Care Advisory Committee, University of North Carolina Hospitals 2000-2003

Lineberger Comprehensive Cancer Center Protocol Review Committee, University of North  
Carolina Hospitals 2000-2005

Lineberger Comprehensive Cancer Center Data Safety and Monitoring Committee, University of  
North Carolina 2002-2005

Bone Marrow Transplant Continuous Quality Improvement Committee, University of North  
Carolina Hospitals 2003-2005

Co-Coordinator, Residency Research Committee, University of North Carolina Hospitals 2003-  
2005

Pharmacy Administration Leadership Committee, Grady Health System

Cancer Center Operations Committee, Grady Health System 2005-2006

Clinical Molecular Testing Utilization Committee, Emory University 2007-2012

Clinical Translational Research Committee, Winship Cancer Institute 2007-present

Vice Chair, Data Safety and Monitoring Committee, Winship Cancer Institute 2007-2016

Hematology/Medical Oncology Fellowship Research Committee, Winship Cancer Institute 2010-  
present

Pediatric Hematology/Medical Oncology Scholarship Oversight Committee 2013-2016

Chair, Data Safety and Monitoring Committee, Winship Cancer Institute 2016-present

Faculty Recruitment Committee, Department of Pharmacology, 2018-present

**13. Peer Review Activities:**

a. Grants:

i. National and International:

National Cancer Institute, The Experimental Therapeutics Clinical Trials Network (UM1/U24)  
Study Section, September 2019.

HOPA Grant Review Committee – Chair, 2015 – 2017

Drug Discovery Review Section, American Cancer Society, Fall 2013, Spring 2014

b. Manuscripts:

*Pharmacotherapy*, 1999 – 2012, 2015- present.

*Journal of Clinical Pharmacology*, 2010 – present.

*Cancer*, 2009 – present.

*Cancer Chemotherapy and Pharmacology*, 2010 – present.

*Journal of Pharmaceutical and Biomedical Analysis*, 2011 – present.

*British Journal of Cancer*, 2012 – present.

*Journal of Clinical Apheresis* 2013 – present.

*Journal of Oncology Pharmacy Practice* 2013-present.  
*Investigational New Drugs* 2015-present.  
*Annals of Oncology*, 2010 – present.  
*Clinical Cancer Research* 2015-present.  
*British Journal of Clinical Pharmacology* 2016-present.  
*PloS One* 2016-present.

c. Conference Abstracts:

i. National and International:

HOPA Annual Meeting, Multiple locations, June 2012-2017

International Society of Oncology Pharmacy Practitioners (ISOPP) Annual Meeting  
Santiago, Chile, April 2016

ASCO Annual Meeting, Developmental Therapeutics – Clinical Pharmacology, Chicago, IL, June 2018

ASCO Annual Meeting, Developmental Therapeutics – Tumor Biology and Clinical  
Pharmacology, Chicago, IL, June 2019

**14. Consultantships/Advisory Boards**

External Advisory Board Member, University of Mississippi Medical Center (UMMC) Cancer Institute, April 2015 – April 2017

External Advisory Board Member, Blood Cancer Network Ireland (BCNI), November 2015 – November 2019

Consultant, Oncology Pharmacology, Genentech Pharmaceuticals, February 2018 – February 2023

Research Team Member, US Food and Drug Administration Project Renewal, April 2019 – present

**15. Editorships and Editorial Boards:**

Section Editor, Original Research, *Journal of Hematology Oncology Pharmacy*, 2010 – 2016

Editorial Board member, *Journal of Oncology Pharmacy Practice*, 2015 – present

Editorial Board member, *Pharmacotherapy*, 2015 – present

**16. Honors and Awards:**

Eagle Scout, 1986

Honors Program, University of North Carolina School of Pharmacy, 1991 – 1994

North Carolina Pharmaceutical Association Women's Auxiliary Scholarship, 1993

Merck Award for Best Honors Project Paper, 1994

William Julius and Vivian Spradlin Smith Scholarship Recipient, 1994

Rho Chi Honor Society, 1996

University of Kentucky Pharmacy Residents Impact Award, 1997

University of North Carolina Residency Award for Excellence in Clinical Practice, 1998

Instructor of the Year, University of North Carolina School of Pharmacy, 2003 – 2004

Fellow, American College of Clinical Pharmacy, 2008

President, Hematology/Oncology Pharmacy Association, 3-year term, 2010

Scholarship grant recipient, Hematology Oncology Practice and Research Network to attend the Focused Investigator Training, American College of Clinical Pharmacy Research Institute, 2013

James R. Eckman Award for Teaching Excellence, 2014

Fellow, Inaugural Class, Hematology/Oncology Pharmacy Association, 2016

Distinguished Graduate, University of North Carolina Hospitals Residency Program, 2017

Appointed to University of North Carolina School of Pharmacy Alumni Association Board of Directors, 2018

Hematology/Oncology Pharmacy Association Award of Excellence, 2018

Clinical Pharmacology member, National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP), pevonedistat and ixazomib project team, 2018

Woodruff Leadership Academy, Fellow, 2019

#### **17. Society Memberships:**

Triangle College of Clinical Pharmacy (TCCP), President 2004 – 2005, 1994 – 2005

North Carolina Association of Pharmacists (NCAP), 1994 – 2005

American Society of Health-System Pharmacists (ASHP), 1993 – present

American College of Clinical Pharmacy (ACCP), 1994 – present

American Society of Hematology (ASH), 2008 – present

American Association for Cancer Research, 2010 – present

American Society of Clinical Pharmacology and Therapeutics, 2016 – present

#### **18. Organization of Conferences:**

##### a. National and International:

##### i. Administrative Positions:

Organizer, “Phase I Clinical Trials: Establishing a Culture and Infrastructure for Conducting Drug Development Studies”. Preconference to the 12<sup>th</sup> Annual Meeting of the Hematology/Oncology Pharmacy Association. Winship Cancer Institute of Emory University, Atlanta, March 2016.

##### ii. Sessions as Chair:

“IGIV Therapy: The Process, The Product, The Patient, and The Pocketbook.” Moderator and presenter (“Intravenous Immune Globulins: Emerging Clinical Applications”), American College of Clinical Pharmacy Annual Meeting, Atlanta, November 2003.

“Controlling Massive Bleeding Episodes: Pharmacoeconomic Issues and Potential Solutions.” Moderator and presenter (“Associated Costs of Transfusion Practices”), American College of Clinical Pharmacy Updates in Therapeutics, Austin, June 2004.

“Practice Panel: Ethics in Oncology.” Hematology Oncology Pharmacy Association 13<sup>th</sup> Annual Meeting, Anaheim, March 2017.

“The Role of Biomarkers in Immunotherapy.” Hematology Oncology Pharmacy Association 14<sup>th</sup> Annual Meeting, Denver, March 2018.

“Preclinical and Clinical Development of Oncology Biosimilars.” American Society of Clinical Oncology, Chicago, June 2018.

## 19. Clinical Service Contributions:

### a. Phase I Clinical Trials Program and Unit Growth at the Winship Cancer Institute

- Since joining in 2007, I have overseen the origination and expansion of the phase I section, with 40 subjects accrued in 2006 to a peak of 251 accrued in 2016.
- I led the design and opening of the first phase I clinical trials unit in 2009 and oversaw the transition to a new facility this year in the Tower, with growth from 11 to 22 treatment areas and 2200 to over 8000 square feet of space. We moved in January 2019.

### b. Data Safety and Monitoring Committee (DSMC)

- I assumed the chair role of the DSMC in May 2016 and have improved the focus and depth of knowledge of the manager and monitors through strategic hiring and oversight. We have spurred educational initiatives and quality improvement processes driven by trial findings; and updated the Data Safety and Monitoring Plan for the P30 that led to cancer center comprehensive status designation in 2017.

## 20. Community Outreach:

### a. General:

Assistant Den Leader, Den 4, Cub Scout Pack 175, Decatur, 2011-2019.

“New Therapies for Multiple Myeloma”. North Atlanta Multiple Myeloma Support Group. Briarcliff United Methodist Church, August 2015, May 2016, May 2017, May 2018, May 2019.

“Optimizing Medicines in People Living with Myeloma”. Southside Atlanta Multiple Myeloma Support Group. Macy’s, Greenbriar Mall. August 2016.

### b. Media Appearances:

American Society of Clinical Oncology (ASCO) sponsored discussion on the role of the oncology pharmacist in cancer care. <http://www.cancer.net/all-about-cancer/cancernet-feature-articles/expert-information-asco/asco-expert-corner-role-oncology-pharmacist>, 2013

American Society of Hematology (ASH) Clinical News, “The Evolving Role of the Hematology/Oncology Pharmacist”. <https://www.ashclinicalnews.org/perspectives/evolving-role-hematologyoncology-pharmacist/>, 2017.

Hematology/Oncology Pharmacy Association (HOPA) interview on the role of biomarkers in predicting response in lung and gastric cancers. <http://www.oncologytube.com/video/pharmacist-s-advice-on-biomarkers-for-immunotherapy/10003616>, 2018.

Fox 5 News, story on novel planning strategy for the Phase I Unit move.

<http://www.fox5atlanta.com/health/fox-medical-team/a-cardboard-cancer-clinic-gives-patients-a-taste-of-what-s-to-come>, 2018.

Medpage, story on survey of oncologists’ perceptions of biosimilars.

<https://www.medpagetoday.com/resource-centers/biosimilars/oncologists-biosimilars-interview-rebecca-pentz-phd-and-r-donald-harvey-pharmd/2426>, 2019.

ASCO Post, interview on data expanding clinical trial eligibility criteria, <https://www.ascopost.com/videos/2019-asco-annual-meeting/richard-schilsky-and-r-donald-harvey-on-expanding-criteria-for-clinical-trial-eligibility/>, 2019.

## 21. Formal Teaching:

### a. Graduate Programs:

#### i. Residency Programs:

Lecture, Medicine Resident Lecture Series, "Design and Conduct of Cancer Clinical Trials." Emory University, May 2015.

#### ii. Fellowship Programs:

Lecture, Hematology/Oncology Fellows, "High Dose Methotrexate with Leucovorin Rescue: Pharmacokinetic/Dynamic Considerations." University of North Carolina, July 1997.

Lecture, Geriatric Fellows, "Pain Management in the Elderly Cancer Patient." University of North Carolina Department of Medicine, April 2002.

Lecture, Pediatric Hematology/Oncology Fellows, "Overview of Antineoplastic Therapy in Pediatrics." University of North Carolina, July and August 2002.

Lecture, Hematology/Oncology Fellows Lecture Series, "Overview of Antiemetic Therapy." Emory University, August 2007-2013.

Lecture, Hematology/Oncology Fellows Lecture Series, "Overview of Antineoplastic Pharmacology." Emory University, August 2007-2017.

Lecture, Pediatric Hematology/Oncology Fellows, "Clinical Pharmacology of Antineoplastic Therapy in Pediatrics." Emory University, August 2008-2016.

Co-Coordinator, with Drs. Pentz and Owonikoko - Fundamentals of Clinical Research, 3-month course for hematology/medical oncology fellows, radiation oncology residents, and surgery fellows. 2009-2018.

#### iii. Master's and PhD Programs:

Lecturer, Cancer Biology Graduate Students. IBS761. "Anticancer Drug Development: From Compound Selection to Clinical Trials". Emory University 2008 – present.

### b. Other Categories:

Lecture, Pharmacy PY-3 Students, "Transfusion Therapy and Blood and Marrow Transplantation." University of North Carolina School of Pharmacy, September 1997-2004.

Lecture, Pharmacy PY-3 Students, "Acquired and Inherited Bleeding Disorders." University of North Carolina School of Pharmacy, September 1998 - 2004.

Lecture, Pharmacy PY-3 Students, "Nutrition Support in Cancer Patients." University of North Carolina School of Pharmacy, February 1999, 2000.

Lecture, Pharmacy PY-3 Students, "Infectious Complications of Chemotherapy." University of North Carolina School of Pharmacy, February 2000-2004.

Lecture, Pharmacy PY-3 Students, "Pediatric Malignancies." University of North Carolina School of Pharmacy, March 2000, 2001.

Lecture, Pharmacists, "Acquired and Inherited Bleeding Disorders." University of North Carolina Hospitals and School of Pharmacy, May 2000.

Lecture, Pharmacists, "Recognition and Management of Heparin-Induced Thrombocytopenia." University of North Carolina Hospitals and School of Pharmacy, August 2000.

Lecture, Pharmacy PY-3 Students, "Acute Leukemias." University of North Carolina School of Pharmacy, October 2000 - 2004.

Lecture, Pharmacy PY-3 Students, "Aplastic Anemia and Myelodysplastic Syndromes." University of North Carolina School of Pharmacy, October 2000.

Lecture, Pharmacy PY-3 Students, "Myeloproliferative Disorders." University of North Carolina School of Pharmacy, March 2001.

Lecture, Pharmacy PY-3 Students, "Phase II Metabolism of Antineoplastic Agents: Focus on Irinotecan." University of North Carolina School of Pharmacy, March 2002, 2004.

Lecture, Pharmacy PY-2 Students, "Overview of Platelet Physiology." University of North Carolina School of Pharmacy, February 2004.

Lecture, Pharmacy PY-2 Students, "Overview of Blood Coagulation." University of North Carolina School of Pharmacy, March 2004.

## 22. Supervisory Teaching:

### a. Other:

Rebekah Matthews, Pharm.D., BCOP, PGY-2 Hematology and Oncology Resident, University of North Carolina, Chapel Hill, 2001-2002. Currently Manager, Pharmacy, Wesley Long Hospital, Greensboro, NC

Stacy (Shifflett) Shord, Pharm.D., FCCP, BCOP (PGY-2 Hematology and Oncology Resident, University of North Carolina, Chapel Hill, 2002-2003). Currently, Associate Director of Labeling, Division of Oncology Products II, Office of Hematology Oncology Products, US Food and Drug Administration, Rockville, MD.

Christine Walko, Pharm.D., BCOP (PGY-2 Hematology and Oncology Resident, University of North Carolina, Chapel Hill, 2003-2004). Currently, Personalized Medicine Specialist, Moffitt Cancer Center, Associate Professor, University of South Florida Morsani College of Medicine, Tampa, FL.

Hillary Prescott, Pharm.D., BCOP (PGY-2 Hematology and Oncology Resident, University of North Carolina, Chapel Hill, 2004-2005). Currently, Manager, Clinical Pharmacy Services and PGY2 Residency Director, Dana-Farber Cancer Institute, Boston.

Marjorie Curry, Pharm.D., BCOP (PGY-2 Hematology and Oncology Resident, Grady Health System Department of Pharmacy, Atlanta, 2005-2006). Currently, Hematology/Oncology Clinical Pharmacy Specialist, Grady Health System, Atlanta.

Colleen Lewis, MSN, ANP-BC, AOCNP, Phase I Program Advanced Practice Provider, Winship Cancer Institute, Atlanta, 2008-present.

Haley Ruffin, Summer Scholars Program 2008. [http://www.mdjonline.com/news/north-cobb-s-ruffin-will-make-medicine-her-life-s/article\\_64470896-c5f9-5cd0-85e7-3f585633dd09.html](http://www.mdjonline.com/news/north-cobb-s-ruffin-will-make-medicine-her-life-s/article_64470896-c5f9-5cd0-85e7-3f585633dd09.html), 2011. Currently, Intern, Quality Improvement Department, Saint Alphonsus Hospital, Boise, ID.

Elisavet Paplomata, M.D. (Chief Fellow, 2013-2014. Emory University School of Medicine, Atlanta). Currently, Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta

Conor Steuer, M.D. (Chief Fellow, 2014-2015. Emory University School of Medicine, Atlanta). Currently, Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta

Meagan Barbee, Pharm.D., BCOP (PGY-2 Hematology and Oncology Resident, Emory Department of Pharmaceutical Services, Atlanta, 2014-2015). Currently, Clinical Coordinator, Oncology Pharmacy, Emory Healthcare and Winship Cancer Institute, Atlanta.

Sarah Wheeler, Pharm.D., BCOP (Chief Resident, PGY-2 Hematology and Oncology, Emory Department of Pharmaceutical Services, Atlanta, 2014-2015). Currently, BMT/Leukemia Clinical Specialist, University of Florida, Gainesville.

Danielle Schlafer, Pharm.D. (PGY-2 Hematology and Oncology Resident, Emory Department of Pharmaceutical Services, Atlanta, 2015-2016.) Currently, Clinical Specialist, Oncology Pharmacy, Emory Healthcare and Winship Cancer Institute, Atlanta.

M. Asim Bilen, M.D. (Assistant Professor, Emory University School of Medicine, Atlanta, Georgia 2016-present)

Sarah Chehab, Pharm.D. (PGY-2 Hematology and Oncology Resident, Emory Department of Pharmaceutical Services, Atlanta, 2016-2017). Currently, Clinical Specialist, Oncology Pharmacy, Moffitt Cancer Center, Tampa, FL.

Kevin Hall, Pharm.D. (PGY-2 Hematology and Oncology Resident, Emory Department of Pharmaceutical Services, Atlanta, 2017-2018). Currently, Clinical Specialist, Oncology Pharmacy, Emory Healthcare and Winship Cancer Institute, Atlanta.

Caroline Redick, Summer Scholars Program at the Winship Cancer Institute, 2018. Currently, Senior at Cambridge High School, Milton.

Lawrence He, Summer Scholars Program at the Winship Cancer Institute, 2019. Currently, Senior at .

### **23. Lectureships, Seminar Invitations, and Visiting Professorships:**

#### **a. National and International:**

1. The Peggy and Charles Stephenson Cancer Center at the University of Oklahoma, "The Use of Pharmacodynamic Endpoints in Early Phase Clinical Trials". Oklahoma City, May 2013.
2. Inaugural Symposium of the Blood Cancer Network in Ireland, "The Recent Evolution of Phase I Trials in Oncology Drug Development", National University of Ireland, Galway, May 2016.
3. National Academy of Sciences, The Drug Development Paradigm in Oncology: A Workshop, "Challenges in Accelerating the Drug Development Paradigm in Oncology", Washington, DC, December 2016.

4. National Academy of Sciences and US Food and Drug Administration, “Updating Labels for Generic Drugs in Oncology”, Washington, DC, March 2019.

b. Regional:

1. Atlanta CTSA Conference on Ethics and Translational Research: From Discovery to Implementation, “Ethical Issues in Anti-Cancer Drug Development: Translating Internal Science.” May 2008.
2. University of North Carolina Lineberger Comprehensive Cancer Center Grand Rounds, “Developmental Immunotherapeutics in Cancer: Clinical Pharmacology Implications”, Chapel Hill, October 2013.
3. 24<sup>th</sup> Annual Fall Cancer Conference, Mary Babb Randolph Cancer Center of West Virginia University, “Cancer, Inflammation, and Therapy: Clinical Pharmacology and Novel Immunotherapeutics”, Morgantown, September 2014.
4. Invited speaker series, Carol and Ray Neag Comprehensive Cancer Center at the University of Connecticut, “Cancer, Inflammation, and Therapy: Clinical Pharmacology and Novel Immunotherapeutics”, Farmington, October 2014.
5. The University of Kentucky Markey Cancer Center Annual Retreat “Establishing a Phase I Trials Unit and Section: The Emory Experience”, Berea, Kentucky, September 2015.
6. The University of Houston College of Pharmacy Seminar Series, “Cancer, Inflammation, and Therapy: Clinical Pharmacology and Novel Immunotherapeutics”, Houston, September 2015.
7. Mercer University College of Pharmacy, “Opportunities for Trainees in Anticancer Drug Development”, Atlanta, October 2017.
8. Department of Pharmacotherapy and Experimental Therapeutics Seminar Series, University of North Carolina School of Pharmacy “Precision, Accuracy, and Resolution: Improving Anticancer Therapies”, Chapel Hill, February 2018.
9. University of Wisconsin Carbone Cancer Center Grand Rounds, “Biosimilars in Oncology: Development, Regulation, and Utilization”, Madison, October 2018.

c. Institutional:

1. Aflac Cancer Center and Blood Disorders Service Research Meeting, Emory University School of Medicine, “Pharmacokinetic and Pharmacodynamic Modeling: Case Studies in Anticancer Drug Development”, January 2008.
2. Cancer Biology Graduate Students Cancer Colloquium, “Drug Development in Cancer – From Preclinical Evaluation to FDA Approval”, February 2013.
3. Discovery and Developmental Therapeutics Program Meeting of the Winship Cancer Institute, “Cancer, Inflammation, and Therapy: Effects on Cytochrome P450-Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Approaches”, July 2014.
4. Pediatric Hematology Oncology Research Group Seminar Series, Aflac Cancer Center of Children’s Healthcare of Atlanta, “Phase I Trials in Adults at the Winship Cancer Institute: A Five-Year Retrospective”, June 2015.

**24. Invitations to National/International, Regional, and Institutional Conferences:**



a. National and International:

1. American Society of Health-System Pharmacists Midyear Clinical Meeting, Clinical Pearls Session, "Too Hot to Trot", Atlanta, December 1997.
2. American College of Clinical Pharmacy Annual Meeting, "IGIV Therapy: The Process, The Product, The Patient, and The Pocketbook." Moderator and presenter ("Intravenous Immune Globulins: Emerging Clinical Applications"), Atlanta, November 2003.
3. American Society of Health-Systems Pharmacists Midyear Clinical Meeting, "Therapeutic Debates in Hematology." Moderator and debater ("Recombinant Factor VIIa is a Cost-Effective Universal Hemostatic Agent"), New Orleans, December 2003.
4. NovoNordisk Pharmaceuticals Workshop On Procoagulants, "Potential Methods of Pharmacodynamic Monitoring of Recombinant Factor VIIa – Opportunities and Pitfalls." Copenhagen, Denmark. January 2004.
5. American College of Clinical Pharmacy 2004 Updates in Therapeutics, "Controlling Massive Bleeding Episodes: Pharmacoeconomic Issues and Potential Solutions." Moderator and presenter ("Associated Costs of Transfusion Practices"), Austin, June 2004.
6. American College of Clinical Pharmacy Annual Meeting, "Managing Acquired and Congenital Bleeding Disorders." Dallas, October 2004.
7. 19<sup>th</sup> Annual Pharmacy Invitational Conference on Antithrombotic Therapy, "Reversal of Excessive Anticoagulation Using Recombinant Factor VIIa: A Case Study." Orlando, Dec 2004.
8. Hematology Oncology Pharmacy Association 1<sup>st</sup> Annual Meeting, "Non-Malignant Hematology: Hemophilia." San Diego, June 2005.
9. American Society of Health-System Pharmacists Midyear Clinical Meeting, "Clinical Considerations in Immune Thrombocytopenic Purpura Therapy Selection." Las Vegas, December 2005.
10. The Oncology Pharmacy Preparatory Review Course. Co-sponsored by the American College of Clinical Pharmacy and the American Society of Health-System Pharmacists, "Acute Leukemia" and "Head, Neck, and Adult CNS Tumors" Fort Lauderdale, May 2006 and Scottsdale, May 2005.
11. Hematology Oncology Pharmacy Association 2<sup>nd</sup> Annual Meeting, "Significant Papers in Hematology: Leukemia and Myelodysplastic Syndromes." Orlando, June 2006.
12. Hematology Oncology Pharmacy Association 3<sup>rd</sup> Annual Meeting, "Therapeutic Debate: Fondaparinux is Safe and Effective in Patients with HIT" Denver, June 2007
13. American College of Clinical Pharmacy Annual Meeting, "Iron Chelation Therapy: An Update on Options", Denver, October 2007.
14. American Society of Health-Systems Pharmacists Midyear Clinical Meeting, "Case Studies in Colorectal Cancer: Targeting EGFRs", Las Vegas, December 2007.
15. Hematology Oncology Pharmacy Association 4<sup>th</sup> Annual Meeting, "Epigenetics in Cancer Medicine". Anaheim, June 2008.
16. American College of Clinical Pharmacy Annual Meeting, "Late Breakers Session – Hematology/Oncology and Transplant/Immunology", Louisville, October 2008.

17. "Novel Treatments in Myelodysplastic Syndromes", American Society of Health-System Pharmacists Annual Meeting, Orlando, December 2008; American College of Clinical Pharmacy Annual Meeting, Louisville, October 2008; and Hematology Oncology Pharmacy Association 4<sup>th</sup> Annual Meeting, Anaheim, June 2008.
18. Hematology Oncology Pharmacy Association 5<sup>th</sup> Annual Meeting, "Best Practices in Investigational Oncology Pharmacy – Phase I Trial Conduct", Miami, June 2009.
19. Hematology Oncology Pharmacy Association 5<sup>th</sup> Annual Meeting, "Iron Overload Management and its Role in Myelodysplastic Syndromes", Miami, June 2009.
20. Hematology Oncology Pharmacy Association 6<sup>th</sup> Annual Meeting, "From Bench to Bedside: Pharmacist Perspectives on Head and Neck Cancer", New Orleans, March 2010.
21. The Board Certification in Oncology Pharmacy (BCOP) Preparatory Review Course. Co-sponsored by the American College of Clinical Pharmacy and the American Society of Health-System Pharmacists, "Lung Cancer" and "Adult Sarcomas". San Diego May 2010, Baltimore, 2009, Tampa 2008.
22. The Board Certification in Oncology Pharmacy (BCOP) Preparatory Review Course. Co-sponsored by the American College of Clinical Pharmacy and the American Society of Health-System Pharmacists, "Lung Cancer" and "Anticancer Drug Development". San Antonio May 2011.
23. Japanese Society of Oncology Pharmacists, "The History and Current Status of Hematology/Oncology Pharmacy Organizations in the United States". Tokyo, December 2011.
24. American College of Clinical Pharmacy Annual Meeting, "Modulating the Immune System in Oncology: The Evolution of Therapy", Pittsburgh, October 2011.
25. American Society of Health-Systems Pharmacy Annual Meeting, "Expanding the Treatment Armamentarium for Non-Small Cell Lung Cancer: Pharmacist Perspectives", New Orleans, December 2011.
26. International Society of Oncology Pharmacy Practitioners Annual Meeting, "Establishment of a Pharmacist-Led Phase 1 Clinical Trials Section", Melbourne, Australia, May 2012.
27. The Board Certification in Oncology Pharmacy (BCOP) Preparatory Review Course. Co-sponsored by the American College of Clinical Pharmacy and the American Society of Health-System Pharmacists, "Lung Cancer" and "Anticancer Drug Development". San Antonio May 2012.
28. American Society of Health-Systems Pharmacy Annual Meeting, "Stop the Bleeding: Updates in Hemophilia Management". Las Vegas, December 2012.
29. American Cancer Executives Annual Meeting, "What Do We Do When The Drugs Run Out? A Pharmacist's Approach to Chemotherapy Shortages". San Antonio, January 2013.
30. Japanese Society of Pharmaceutical Oncology, "The Road Not Travelled: Current and Future Opportunities for Oncology Pharmacists". Tokyo, Japan, March 2013.
31. The Association of Community Cancer Centers (ACCC) National Oncology Conference, "Philadelphia (Chromosome) Freedom?: An Update on Novel Therapies for CML". Boston, October 2013.

32. BMT Tandem Meetings. "Practice Management Strategies for Dosing and Drug Administration in Multiple Myeloma", Grapevine, Texas. February 2014.
33. Hematology Oncology Pharmacy Association 10<sup>th</sup> Annual Meeting, "How to Develop and Submit a High Quality Research Proposal". New Orleans, March 2014.
34. Hematology Oncology Pharmacy Association 10<sup>th</sup> Annual Meeting, "Selected Agents in Development for Hematologic and Solid Tumor Malignancies". New Orleans, March 2014.
35. American Society of Health-Systems Pharmacy Annual Meeting, "New and Emerging Strategies for the Treatment of Advanced Melanoma". Anaheim, December 2014.
36. Hematology Oncology Pharmacy Association 11<sup>th</sup> Annual Meeting, "Clinical Considerations in Patients with Myeloma and Renal Impairment". Austin, March 2015.
37. International Pharmaceutical Federation (FIP) World Congress, "Targeting Programmed Cell Death-1 (PD-1) in Cancer Treatment". Dusseldorf, Germany, October 2015.
38. Annual Meeting of the Advanced Practitioner Society for Hematology and Oncology, "Navigating Targeted Therapies for Advanced Non-Small Cell Lung Cancer", Phoenix, November 2015.
39. American Society of Health System Pharmacists, "Novel Approaches and Interventions in Acquired Hemophilia." New Orleans, December 2015.
40. Armada Specialty Pharmacy Summit, "Testing to Target in Non-Small Cell Lung Cancer – Managed Care Perspectives." Las Vegas, May 2016.
41. American College of Clinical Pharmacology Annual Meeting, "Clinical Perspectives in Combinations, Requirements and Challenges in Small- and Large-Molecule Oncology Drug Development." Bethesda, September 2016.
42. Advanced Practitioner Society for Hematology and Oncology (APSHO) Annual Meeting, "Newly Approved Agents in Hematologic Malignancies 2015-2016." Washington, DC, November 2016.
43. Hematology Oncology Pharmacy Association 13<sup>th</sup> Annual Meeting, "Practice Panel: Ethics in Oncology." Anaheim, March 2017.
44. International Society of Oncology Pharmacy Practitioners XVI Annual Meeting, "Immunotherapeutic Strategies in Myeloma." Budapest, April 2017.
45. American College of Clinical Pharmacology Annual Meeting, "Pharmacodynamics of Kinase Inhibitors in Children: Markers of Effect and Mechanisms of Resistance". San Diego, September 2017.
46. International Society of Oncology Pharmacy Practitioners XVII Annual Meeting, "Novel Trial Designs in Oncology." Shanghai, April 2018.
47. American Association of Cancer Institutes Annual Meeting, "Modernizing Eligibility Criteria in Oncology Trials." Chicago, May 2018.
48. American Society of Clinical Oncology Annual Meeting, "The Science and Process for Biosimilars." Chicago, June 2018.
49. Quality Cancer Care Alliance Leadership Meeting, "The Science and Process of Biosimilar Development and Use." Chicago, August 2018.

50. International Society for Pharmacoepidemiology Mid-year Meeting, "Perspectives from Scientific Societies on Biologic and Biosimilar Use: The American Society of Clinical Oncology". Rome, Italy, April 2019.

b. Regional:

1. North Carolina Association of Pharmacists Winter Meeting, "Novel Approaches to Anticoagulation: The Pharmacist's Role." Greensboro, March 2001.
2. Triangle chapter of The Leukemia and Lymphoma Society, "Novel Agents for the Treatment of Hematologic Malignancies." Raleigh, December 2003.
3. North Carolina Area Health Education Centers, "Novel Approaches to Thromboembolic Disease Prevention and Treatment." February-April 2004.
4. Coastal Area Health Education Center, "Update in Oncology Therapeutics." Wilmington, April 2004.
5. North Carolina Oncology Pharmacists Network, "Update in Supportive Care: Nausea/Vomiting and Pain Management." Greensboro, August 2004.
6. Fourth Annual Oncology Nurses Association Curriculum, "Toxicities and Tolerability of Antineoplastic Therapy." March 2005.
7. North Carolina Association of Pharmacists Acute Care Meeting, "An Update on Non-Hemophilia Uses of Recombinant Factor VIIa." March 2005.
8. North Carolina Oncology Pharmacists Network, "Update in Hematological Malignancies." Greensboro, August 2005.
9. South Carolina Oncology Nursing Society, "Update on the Management of Chronic Myeloid Leukemia." Greenville, April 2006.
10. North Carolina Oncology Pharmacists Network, "Therapeutic Debate: FCR is Optimal Initial Therapy in Chronic Lymphocytic Leukemia." Greensboro, August 2006.
11. North Carolina Oncology Pharmacists Network, "Challenging Cases in Hematology/Oncology Pharmacotherapy." Greensboro, August 2007.
12. North Carolina Oncology Pharmacists Network, "Update on Procoagulant Use." Greensboro, August 2008.
13. Oklahoma Society of Clinical Oncology, "Non-Small Cell Lung Cancer: Focus on the Integration of New Agents", Oklahoma City, January 2009.
14. Oncology Nursing Symposium, "Update on Novel Therapies in the Management of Hematologic and Oncologic Disorders", Stone Mountain, Georgia, March 2009.
15. Kansas Oncology Nursing Society Annual Meeting, "Drug Development in Hematologic Malignancies – Novel Target Inhibition", Lawrence, July 2009.
16. North Carolina Oncology Pharmacists Network, "Emerging Pathways and Drug Development in Cancer", Greensboro, August 2009.
17. Oncology Nursing Symposium, "Anticancer Drug Development: Emerging Pathways and Clinical Trial Data", Stone Mountain, Georgia, March 2010.

18. Georgia Chapter of the Leukemia and Lymphoma Society Patient Conference, "Drug Development in Hematologic Malignancies: Novel Compounds on the Horizon", Atlanta, March 2010.
19. "Chronic Myeloid Leukemia: Considerations for Selecting and Managing Therapy", Georgia Society of Health-System Pharmacists Annual Meeting, Helen, October 2010, Alabama Society of Health-System Pharmacists Annual Meeting, Birmingham, October 2010; American Society of Health-System Pharmacists Summer Meeting, Tampa, June 2010; Ohio Society of Health-System Pharmacists Annual Meeting, Columbus, April 2010.
20. Cancer and Leukemia Group B Summer Meeting, "Pharmacogenomics and Treatment Implications in Cancer", Chicago, June 2010.
21. North Carolina Oncology Pharmacists Association, "Therapeutic Debate: R-CHOP Remains the Gold Standard for Follicular Lymphoma", Cary, August 2010.
22. North Carolina Oncology Pharmacists Association, "Therapeutic Debate: Cisplatin is the Superior Platinum Agent in the Initial Treatment of Unresectable NSCLC", Cary, August 2011.
23. Northeast Regional Hematology/Oncology Pharmacists Symposium, "Pursuing the Plasma Cell: Novel Approaches in Multiple Myeloma Therapeutics", Boston, October 2011.
24. Smith Drug Regional Meeting, "Novel Approaches Using Immunotherapy in Advanced Melanoma", Asheville, NC, July 2012.
25. North Carolina Oncology Pharmacists Association, "Therapeutic Debate: Second Generation Tyrosine Kinase Inhibitors are Superior to Imatinib in the Initial Treatment of Chronic Phase CML", Cary, August 2012.
26. Pharmacy Learning Network, "Advances in the Treatment of Non-Small Cell Lung Cancer", Washington, DC, August 2012; Los Angeles, September 2012.
27. Northeast Regional Hematology/Oncology Pharmacists Symposium, "Treating Patients with Relapsed or Refractory Multiple Myeloma: Current and Emerging Options", Boston, October 2012.
28. Pharmacy Learning Network, "Advances in the Treatment of Non-Small Cell Lung Cancer", Philadelphia, November 2012, Orlando, March 2013; Pittsburgh, September 2013.
29. Northeast Regional Hematology/Oncology Pharmacists Symposium, "Novel Treatment Approaches to Patients Across the Myeloma Spectrum", Boston, October 2013.
30. North Carolina Oncology Pharmacists Association, "Therapeutic Debate: ChemoBrain: Real or Imagined?". Cary, August 2014.
31. Northeast Regional Hematology/Oncology Pharmacists Symposium, "How We Treat Multiple Myeloma Patients with Renal Dysfunction". Boston, October 2014.
32. Kentucky Society of Health-System Pharmacists Annual Meeting, "New and Emerging Strategies for the Treatment of Advanced Melanoma". Lexington, May 2015.
33. Oncology Pharmacy Education Network (OPEN) Regional Clinical Meeting, "Case Studies in Multiple Myeloma: Integrating Novel Agents into Practice". New Brunswick, NJ, May 2015, Fort Lauderdale, June 2015.

34. Louisiana Society of Health-System Pharmacists Annual Meeting, "New and Emerging Strategies for the Treatment of Advanced Melanoma". New Orleans, May 2015.
35. North Carolina Oncology Pharmacists Association, "Therapeutic Debate: PD-L1 Testing Predicts Outcome in Non-Small Cell Lung Cancer Treatment". Cary, August 2016.
36. Northeast Regional Hematology/Oncology Pharmacists Symposium, "Immune Based Strategies for Myeloma: Combining Antibodies for Optimal Outcomes", Boston, October 2016.
37. JADPRO Regional Lectures: Immunotherapy, "Overview of the Immune System" "Case Studies in NSCLC and RCC". Chicago, September 2017; Pittsburgh, October 2017; New York, April 2018; Anaheim October 2018.
38. Northeast Regional Hematology/Oncology Pharmacists Symposium, "Updates in Myeloma Therapeutics: Bone Health, Smoldering Disease, and CAR-T Cells", Boston, October 2018.

c. Institutional:

1. Winship Cancer Institute of Emory University Grand Rounds, "Rapid Immunoassays for Pharmacokinetically-Guided Antineoplastic Individualization", Atlanta, February 2008.
2. Winship Cancer Institute of Emory University Grand Rounds, "The Art and Science of Phase I Trials", Atlanta, June 2011.
3. 5<sup>th</sup> Annual Gastrointestinal Cancers Symposium, Emory Department of Hematology and Medical Oncology, "Immunotherapy and Novel Targeted Agents for GI Malignancies", Atlanta, November 2014.
4. Winship Cancer Institute of Emory University Grand Rounds, "Precision, Accuracy, and Resolution – Dose Selection of Oral Anticancer Agents". Atlanta, May 2015.
5. Winship Cancer Institute of Emory University Debates and Didactics in Hematology and Oncology, "The Evolution of the Phase I Trial in Oncology". Sea Island, July 2017.
6. Winship Cancer Institute of Emory University Grand Rounds, "Biosimilars in Oncology: Considerations from Development to Treatment". Atlanta, September 2017.
7. Winship Cancer Institute of Emory University Debates and Didactics in Hematology and Oncology, "How Phase I Trials Can Improve your Patient Outcomes". Sea Island, July 2018.

**25. Abstract Presentations at National/International, Regional, and Institutional Conferences:**

a. National and International:

**Harvey RD\***, Shea T, Walko C, Krasnov C, Patel L, Serody J, Gabriel D, Comeau T, Lindley C. Intravenous busulfan test dose clearance comparison with first and thirteenth dose systemic exposure in allogeneic bone marrow transplant recipients. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2005 (poster presentation).

**Harvey RD\***, Kauh JS, Ramalingam SS, Lewis CM, Chen Z, Lonial S, Blount IC, Shin DM, Khuri FR, Owonikoko TK. Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2010 (poster presentation).

**Harvey RD\***, Lewis CM, Kauh JS, Owonikoko TS, Akintayo A, Karol M, Teofilovici F, Khuri FR, Ramalingam SS. A phase 1 and pharmacokinetic study of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel in patients with advanced solid tumor malignancies. European Society of Medical Oncology Annual Meeting, Amsterdam, 2011 (poster presentation).

**Harvey RD\***, Lonial S, Renfro H, Sinha R, Flowers CR, Lechowicz MJ, Khoury HJ, Langston A, Waller EK, Kaufman JL. Temporal changes in plerixafor administration do not impact hematopoietic stem cell mobilization efficacy: Results of a prospective clinical trial. American Society of Hematology Annual Meeting, San Diego, CA, 2011 (poster presentation).

**Harvey RD\***, Jacobus SJ, Rajkumar SV, Greipp PR, Lonial S. Renal function measures improve on lenalidomide and dexamethasone and compete with patient characteristics to predict lenalidomide dose density and hematologic toxicity: An E4A03 analysis. American Society of Hematology Annual Meeting, San Diego, CA, 2011 (poster presentation).

**Harvey RD\***, Lewis CM, Pillai R, Lawson D, Ramalingam SS, Morgan ET. Novel Immunotherapeutics and Concurrent CYP Substrate Use in Advanced Cancer. International Society of Oncology Pharmacy Practitioners Annual Meeting, Santiago, Chile, 2014 (poster presentation).

**Harvey RD\***, Chen YJ, Lethen J, Mahue M. Relationship of carfilzomib dosing and duration of therapy (DOT) in patients with relapsed and refractory multiple myeloma (RRMM). American Society of Hematology Annual Meeting, Orlando, FL, 2015 (poster presentation).

**Harvey RD\***, Gore L, Wang D, Mita A, Sharma S, Nemunaitis J, Papadopoulos K, Pinchasik D, Ou Y, Demirhan E, Cutler RE, Tsimberidou AM. A phase I study to assess food effect on oprozomib in patients with advanced malignancies. American Society of Clin Pharmacol Ther 2016: PII-090 (poster presentation).

**Harvey RD\***, Kaufman JL, Heffner LT, Hofmeister CC, Dhodapkar MV, Lonial S, Nooka AK. Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2018 (poster presentation).

## 26. Research Focus:

My research focuses on the application of clinical pharmacology principles to improve cancer treatment outcomes. Investigations of drug disposition, novel agents and development strategies, and social aspects of care drives the work we do in our Phase I Clinical Trials Program.

## 27. Grant Support:

### a. Active Support (PI or Co-PI role):

#### i. Contracts:

**PI:** Halozyme, *A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors*, \$23,330/patient enrolled, 2015 – 2021.

**PI:** Incyte, *A Phase 1/2 Study of INCB053914 in Subjects with Advanced Malignancies*, \$31,626/patient enrolled, 2015 – 2021.

**PI:** Celgene (Acetylon Pharmaceuticals), *A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY-241 in Combination with Paclitaxel in Patients with Advanced Solid Tumors*, \$17,830/patient enrolled, 2016 – 2022.

**Co-PI:** Pfizer, *A Phase I Study of Palbociclib in Combination with Cisplatin or Carboplatin in Advanced Solid Malignancies*, \$1,286,955, 2016 – 2022.

**Co-PI:** Genmab, *First-in-Human, Open-Label, Dose Escalation Trial with Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax®-AXL-ADC) in Patients with Solid Tumors*, \$85,531/patient enrolled, 2017 – 2027

**PI:** Rgenix, *A Phase I Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma*, \$28,671/patient enrolled, 2017 – 2027.

**PI:** Takeda, *A Phase Ib Study to Evaluate TAK-659 in Combination with Nivolumab in Patients With Advanced Solid Tumors*, \$60,424/patient enrolled, 2017 – 2027.

**PI:** Meryx, *A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors*, 2018 – 2028. \$730,105

**PI:** Xencor, *A Phase I Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors*, \$54,389/patient enrolled, 2018 – 2028.

**PI:** Tesaro, *An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients with Advanced Solid Tumors*, \$9,173/patient enrolled, 2018 – 2028.

b. Active Support (Co-Investigator role)

i. Federally Funded

**Co-I:** NIH,4UH3AI122320-03, *Development of Gleevec for TB and TB/HIV*, \$ 3,162,269, 2015-2020.

ii. Contracts

**Co-I:** AstraZeneca Pharmaceuticals, *An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 following a Single Oral Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment*, \$15,116/patient enrolled, 2014-2020

**Co-I:** AstraZeneca Pharmaceuticals, *An Open-label, Randomised, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Doses of AZD9291 in Patients with EGFRm Positive NSCLC whose Disease has Progressed on an EGFR TKI*, \$19,721/patient enrolled, 2014-2020

**Co-I:** AstraZeneca Pharmaceuticals, *A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients with EGFRm Positive NSCLC Whose Disease has Progressed on an EGFR TKI*, \$22,926/patient enrolled 2014-2020

**Co-I:** AstraZeneca Pharmaceuticals, *A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of Rifampicin (a CYP3A4 Inducer) on the Pharmacokinetics of AZD9291 in Patients with EGFRm Positive NSCLC whose disease has Progressed on an EGFR TKI*, \$19,750/patient enrolled, 2014-2020



**Co-I:** AstraZeneca Pharmaceuticals, *A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Simvastatin (a Sensitive CYP3A4 Substrate) in Patients with EGFRm Positive NSCLC whose disease has Progressed on an EGFR TKI*, \$19,187/patient enrolled 2014-2020

**Co-I:** Arqule, *A Phase I Dose Escalation Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors*, \$15,853/patient enrolled, 2015-2021

**Co-I:** Pfizer Pharmaceuticals, *A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PF-06650808 in Patients with Advanced Solid Tumors*, \$19,756/patient enrolled 2015-2021

**Co-I:** Syndax Pharmaceuticals, *A Phase 1b/2 Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch-Repair Proficient Colorectal Cancer*, \$14,442/patient enrolled 2015-2021

**Co-I:** Boston Biomedical, Inc. *A Phase Ib/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers*, \$14,713/patient enrolled, 2015-2021

**Co-I:** BMS, *Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors*, \$24,082/patient enrolled, 2015-2021

**Co-I:** Ignyta, *STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements*, \$9080/patient enrolled, 2015-2021

**Co-I:** Eli Lilly, *Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF<sub>1</sub> Receptor (CSF-1R), in Subjects with Advanced Solid Tumors Refractory to Standard Therapy or for which No Standard Therapy is Available*, \$33,103/patient enrolled, 2016-2022

**Co-I:** Regeneron, *A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death 1 (PD-1), as Single Therapy and in Combination with Other Anticancer Therapies in Patients with Advanced Malignancies*, \$36,485/patient enrolled, 2016-2022

**Co-I:** Five Prime Therapeutics, *A Phase 1a/1b Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers*, \$37,508/patient enrolled, 2016-2022

**Co-I:** Vertex Pharmaceuticals, *An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination with Cytotoxic Chemotherapy in Subjects with Advanced Solid Tumors*, \$2,045,412.24, 2016-2022

**Co-I:** Pfizer, *A Phase 1 Study of PF-05082566 as a Single Agent in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin's Lymphoma*, \$2,035,815.02, 2016-2022

**Co-I:** BMS, *A Phase 1/2a Study of BMS-986205 in Combination with Nivolumab and in Combination with both Nivolumab and Ipilimumab in Advanced Malignant Tumors*, \$34,185/patient enrolled, 2016-2022

**Co-I:** Corvus Pharmaceuticals, *A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers*, \$29,608/patient enrolled, 2016-2022

**Co-I:** Eli Lilly, *A Phase 1/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination with Durvalumab (MEDI4736) or Tremelimumab in Patients with Advanced Solid Tumors*, \$46,596/patient enrolled, 2016-2022

**Co-I:** Nektar Therapeutics, *A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies*, \$35,624/patient enrolled, 2016-2018

**Co-I:** Abbvie (Stemcentrx), *An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors*, \$2,017,000, 2016-2022

**Co-I:** Amgen, *A Phase 1b/2 Study Assessing Safety and Anti-Tumor Activity of AMG820 in Combination with Pembrolizumab in Select Advanced Solid Tumors*, \$39,897/patient enrolled, 2016-2022.

**Co-I:** BMS, *A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of anti-GITR Monoclonal Antibody (BMS-986156) Administered Alone and in Combination with Nivolumab in Advanced Solid Tumors*, \$42,455/patient enrolled, 2017-2027

c. Previous Support (PI or Co-PI role):

i. Federally Funded

**Co-PI:** H. Lee Moffitt Cancer Center and Research Institute (Southeast Phase 2 Consortium), *NCI 8063: A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction*, \$4500/patient enrolled, 2008–2011

ii. Private Foundation

**PI:** PPD Bioanalytical Fluid and Tissue Grant Award of the American College of Clinical Pharmacy (ACCP) Research Institute, *Defining the Interaction of Docetaxel and Lonafarnib in Advanced Malignancies*, \$3000 award plus direct costs of docetaxel sample analysis, 2009

iii. Contracts

**PI:** Onyx Pharmaceuticals, *A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction with Midazolam and Safety and Tolerability in Patients with Advanced Malignancies*, \$20,535/patient enrolled, 2014 – 2018.

**Co-PI:** ImClone Systems, *A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients with Advanced Cancer*, \$142,802, 2010 – 2014.

**PI:** Genzyme Corporation, *Phase II Study of Time of Administration of Plerixafor (Mozobil®, AMD3100) in Combination with G-CSF on Safety and CD34+ Cell Mobilization*, \$214,917, 2010 – 2014.

**Co-PI:** Genzyme Corporation, *Evaluation of Plerixafor (Mozobil®, AMD3100) in Combination with Chemotherapy and G-CSF for CD34+ Cell Mobilization*, \$216,190, 2010 – 2014.

**Co-PI:** Pfizer, *A Phase I Study of Axitinib and Temsirolimus in Solid Tumors*, \$295,925, 2011 – 2012.

**Co-PI:** H. Lee Moffitt Cancer Center and Research Institute (Southeast Phase 2 Consortium). *NCI 8846: Phase I, Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction*. \$46,780, 2011 – 2013.

**PI:** Eisai Incorporated, *An Open-Label Phase 1 Study to Assess the Pharmacokinetics and Safety of Eribulin in Subjects With Cancer Who Also Have Impaired Renal Function*, \$54,700, 2012-2016.

**PI:** Novartis Pharmaceuticals, *Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients with Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma*, \$201,202. 2014 – 2016.

**PI:** Millennium Pharmaceuticals, *A Phase 1B, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients with Solid Tumors*, \$11,085/patient enrolled, 2013 – 2017.

**PI:** Millennium Pharmaceuticals, *A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors*, \$236,886, 2014 – 2018.

**Co-PI:** Onyx Pharmaceuticals, *A Phase I Study of Extended Infusion Carfilzomib on a Weekly Schedule in Patients with Advanced Solid Malignancies.* \$479,991. 2014 – 2018.

d. Previous Support (Co-Investigator role):

i. Federally Funded

**Co-I:** NCI, 2 R56 CA094233-06A1, *Vascular Targeted Pan PI-3 Kinase Inhibitor Prodrug, SF 1126, for Glioma Therapy*, 2001 – 2009.

**Co-I:** NIH/NCI, R21CA141836, *Using Proton MRS to Predict Response of SAHA treatment in Glioblastoma.* 2010 – 2012

**PI:** N01-CM-62208-16 NCI CTEP Phase II Trial Consortium, \$629,300, 2013 – 2016.

ii. Contracts

**Co-I:** Cleave Biosciences, *A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors*, \$28,702/patient enrolled, 2014-2018.

**Co-I:** Cleave Biosciences, *A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients with Relapsed/Refractory Multiple Myeloma*, \$24,853/patient enrolled, 2014-2018.

**Co-I:** Calithera Biosciences, *A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies*, \$13,480/patient enrolled, 2014-2018.

**Co-I:** Calithera Biosciences, *A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Solid Tumors*, \$18,016/patient enrolled, 2014-2018

**Co-I:** BMS Pharmaceuticals, *Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-906024 in Subjects with Advanced Solid Tumors*, \$26,749/patient enrolled 2014-2018

**Co-I:** Sanofi Pharmaceuticals, *A Phase I Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies*, \$25,550/patient enrolled, 2014-2019

**Co-I:** Abbott Laboratories, *A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-348 in Subjects with Advanced Hematologic Malignancies*, \$316,819, 2010 – 2014.

**Co-I:** Acetylon Pharmaceuticals, *A Phase I/II, Open-Label, Multi-Center Study of ACY-1215 Administered Orally As Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma*, \$11,365/patient enrolled, 2011 – 2015.

**Co-I:** Celgene Corporation, *Phase I Study of Everolimus (RAD001) in Combination with Lenalidomide in Patients with Advanced Solid Malignancies Enriched for Renal Cell Carcinoma*, \$247,136, 2010 – 2016.

**Co-I:** Novartis Pharmaceuticals, *A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies*, \$509,832, 2011 – 2015.

**Co-I:** Aveo Pharmaceuticals, *A Phase 1 Open-Label, Multiple Dose, Dose Escalation Study Of Monoclonal Antibody AV-203 Administered In Subjects With Metastatic or Advanced Solid Tumors*, \$17,062/patient enrolled, 2012 – 2016

**Co-I:** Onyx Pharmaceuticals, *Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of ONX 0912 in Patients with Hematological Malignancies*, \$15,201/patient enrolled, 2012 – 2016.

**Co-I:** Amgen, *An Open-Label, Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects with Normal and Impaired Renal Function*, \$11,649/patient enrolled, 2012 – 2016.

**Co-I:** Agensys Pharmaceuticals, *A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E Given as Monotherapy Followed By Expansion Cohorts in Subjects with Malignant Solid Tumors that Express Nectin-4*, \$145,619, 2013 – 2016.

**Co-I:** Merck Pharmaceuticals, *Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma*, \$746,762, 2013 – 2017.

**Co-I:** Celgene, *A Phase I Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma and Impaired Renal Function*, \$23,344/patient enrolled, 2014 – 2018.

**Co-I:** Millennium Pharmaceuticals, *Phase 1/1b Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients With Normal Renal Function or Severe Renal Impairment*, \$16,880/patient enrolled, 2014 – 2017.

## 28. Bibliography:

- a. Published and Accepted Research Articles (clinical, basic science, other) in Refereed Journals:

1. Baker J, McCune JS, **Harvey RD**, Bonsignore C, Lindley CM. Granulocyte colony-stimulating factor use in cancer patients. *Ann Pharmacother* 2000;34:851-857. PMID: 10928394
2. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, **Harvey D**. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. *Bone Marrow Transplantation* 2001;28:405-407. PMID: 11571515
3. Treish I, Shord S, Valgus J, **Harvey D**, Nagy J, Stegall J, Lindley C. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy. *Support Care Cancer* 2003;11:516-521. PMID: 12836088
4. Lindley C, Shea T, McCune J, Shord S, Decker J, **Harvey D**, Petros WP, Gabriel D, Serody J, Kirby S, Wiley J. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. *Anticancer Drugs*. 2004;15:453-9. PMID: 15166618
5. Gabriel DA, Shea TC, Serody JS, Moore DT, Kirby SL, **Harvey D**, Krasnov C. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. *Biol Blood Marrow Transplant* 2005;11:1022-1030. PMID: 16338625
6. Kelly H, **Harvey D**, Moll S. A cautionary tale: Fatal outcome of methotrexate therapy given for management of ectopic pregnancy. *Obstet Gynecol* 2006;107:439-441. PMID: 16449141
7. Coghill J, Comeau T, Shea T, Braddy L, Bandarenko N, Afeni-Annan A, **Harvey D**. Acute hemolysis in a patient with cytomegalovirus pneumonitis treated with intravenous immunoglobulin (IVIG). *Biol Blood Marrow Transplant* 2006;12:786-788. PMID: 16785068
8. **Harvey RD**, Nettles J, Wang B, Sun S-Y, Lonial S. Commentary on Perrone et al.: "Vitamin C: not for breakfast anymore ... if you have myeloma". *Leukemia* 2009;23:1939-1940. PMID: 19904281
9. **Harvey RD**, Khuri FR, Kauh JS. Through the looking glass: the evolution of erythropoiesis-stimulating agent use. *Oncology (Williston Park)* 2010;24:269-274. PMID: 20394139
10. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, **Harvey RD**, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. *J Clin Oncol* 2010;28:3015-3022. PMID: 20479412
11. Ramalingam SS, **Harvey RD**, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin MJ, Fu H, Khuri FR. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. *Cancer* 2010;116:3903-3909. PMID: 20564143
12. Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston A, Heffner LT, Torre C, McMillan S, Renfro H, **Harvey RD**, Lechowicz MJ, Khoury HJ, Flowers C, Waller EK. A phase I/II trial combining high dose melphalan and autologous transplant with bortezomib for multiple myeloma: A dose and schedule finding study. *Clin Cancer Res* 2010; 16:5079-5086. PMID: 20739431
13. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, **Harvey RD**, Ivy SP, Belani CP, Egorin MJ. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. *J Clin Oncol* 2010;28:4507-4512. PMID: 20837947
14. Renfro H, Arnold M, Vaughn L, **Harvey RD**, Hamilton E, Lonial S, Khoury HJ, Kaufman JL, Lechowicz MJ, Flowers CR, Waller EK. A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. *Transfusion*. 2011;51:1779-1783. PMID: 21332729

15. Kempton CL, Meeks SL, **Donald Harvey R 3rd**, Abshire TC. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII. *Haemophilia*. 2011;17:155-6. PMID: 20579112
16. Kauh J, Chanel-Vos C, Escuin D, Fanucchi MP, **Harvey RD**, Saba N, Shin DM, Gal A, Pan L, Kutner M, Ramalingam SS, Bender L, Marcus A, Giannakakou P, Khuri FR. Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. *Cancer* 2011;117:4049-4059. PMID: 21365629
17. Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, Tighiouart M, Vertino PM, **Harvey RD**, Garcia A, Marcus AI. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inhibiting vimentin disassembly and serine 56 phosphorylation. *Int J Cancer* 2011;129:2744-2755. PMID: 21538350
18. Pentz RD, White M, **Harvey RD**, Farmer ZL, Liu Y, Lewis C, Dashevskaya O, Owonikoko T, Khuri FR. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. *Cancer* 2012;118:4571-4578. PMID: 22294385
19. Pentz RD, **Harvey RD**, White M, Farmer ZL, Dashevskaya O, Chen Z, Lewis C, Owonikoko TK, Khuri FR. Research biopsies in phase I studies: Views and perspectives of participants and investigators. *IRB* 2012;34:1-8. PMID: 22512092
20. Bethelmie-Bryan B, Lord K, Holloway S, Safavi F, Shepard M, Rogers S, **Harvey RD**, Rodger K, Waller EK, El-Rayes B, Arellano M, Khoury HJ. Tools to optimize the functionality of a leukemia clinical trial team. *Leuk Lymphoma* 2013;54:110-116. PMID: 22762552
21. Wilson N, Surati M, Walker Bf, Kaufman JL, **Harvey RD**. Bortezomib administration with severe hyperbilirubinemia due to hepatic plasma cell infiltration: A case report. *Clin Lymphoma Myeloma Leuk* 2013;13:159-161. PMID: 23084405
22. **Harvey RD**, Owonikoko TK, Lewis CM, Akintayo A, Chen Z, Tighiouart M, Ramalingam SS, Fanucchi M, Nadella P, Rogatko A, Shin DM, El-Rayes B, Khuri FR, Kauh JS. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. *Br J Cancer* 2013;108:762-765. PMID: 23322195
23. Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba N, Kono SA, Gal AA, Sica G, **Harvey RD**, Chen Z, Klass CM, Shin DM, Fu H, Sun SY, Govindan R, Khuri FR. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. *J Thorac Oncol* 2013;8:369-372. PMID: 23407561
24. Shibata S, Chung V, Synold T, Longmate J, Suttle B, Lenz HJ, Kummar S, **Harvey RD**, Hamilton A, O'Neil B, Sarantopoulos J, El-Khoueiry A, Lorusso P, Rudek M, Dowlati A, Mulkerin D, Ivy SP, Newman E. Phase 1 study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. *Clin Cancer Res*. 2013;19:3631-3639. PMID: 23653147
25. **Harvey RD**, Kaufman JL, Johnson HR, Vaughn L, Nooka A, Sinha R, Khoury HJ, Lechowicz MJ, Langston AA, Lonial S, Waller EK. Temporal changes in plerixafor administration do not impact hematopoietic stem cell mobilization efficacy: Results of a prospective clinical trial. *Biol Blood Marrow Transplant*. 2013;19:1393-1395. PMID: 23764455
26. Siegel D, Martin T, Nooka A, **Harvey RD**, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCullough L, Rajangam K, Lonial S. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies. *Haematologica* 2013;98:1753-1761. PMID: 23935022
27. Koura DT, Horan JT, Langston A, Qayed M, Mehta A, Khoury HJ, **Harvey RD**, Suessmuth Y, Couture C, Carr J, Grizzle A, Johnson HR, Cheeseman JA, Conger JA, Robertson J, Stempora L, Johnson BE, Garrett A, Kirk AD, Larsen CP, Waller EK, Kean LS. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: A first in disease trial. *Biol Blood Marrow Transplant*. 2013;19:1638-1649. PMID: 24047754

28. Barbee MS, **Harvey RD**, Lonial S, Kaufman JL, Wilson NM, McKibbin T, Hutcherson DA, Surati M, Valla K, Shah KS. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. *Ann Pharmacother* 2013;47:1136-1192. PMID: 24259728
29. Nooka AK, **Harvey RD**, Langston A, Collins H, Lonial S, Kaufman JL. Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: A case series. *Clin Lymphoma Myeloma Leuk* 2014;14:e59-63. PMID: 24378319
30. Barbee MS, Owonikoko TK, **Harvey RD**. Taxanes: Vesicants, irritants, or just irritating? *Ther Adv Med Oncol* 2014;6:16-20. PMID: 24381657
31. Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, **Harvey RD**, Chen J, Sun SY, Boise LH, Lonial S. MLN4924, an investigational NAE inhibitor, suppresses AKT and mTOR signaling pathway through up regulating REDD1 in human myeloma cells. *Blood* 2014;22:3269-3276. PMID: 24713927
32. Tran DQ, **Harvey RD**, Meeks SL, Chapman R, Kempton CL. Use of factor VIII after inhibitor clearance in patients with moderate hemophilia: A case series. *Haemophilia* 2014;20:e344-346. PMID: 24750497
33. Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, **Harvey RD**, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly dosing of investigational oral proteasome inhibitor ixazomib in patients with relapsed and/or refractory multiple myeloma. *Blood* 2014;14:1038-1046. PMID 24920586
34. Raje N, Faiman B, **Harvey RD**, Kurtin SE, Lonial S, Kumar SK, Cohen AD, Conde MA, Giralt SA, Recine MS, Tomblar ER, Stadtmauer E, Jagannath S, Anderson KC. Identifying professional education gaps and barriers in multiple myeloma patient care: Findings of the *Managing Myeloma* continuing educational initiative advisory committee. *Clin Lymphoma Myeloma Leuk* 2014;14:356-369. . PMID: 25066040
35. Saba NF, Hurwitz SJ, Magliocca K, Kim S, Owonikoko TK, **Harvey D**, Ramalingam SS, Chen Z, Rogerio J, Mendel J, Kono SA, Lewis C, Chen AY, Higgins K, El-Deiry M, Wadsworth T, Beitler JJ, Shin DM, Sun SY, Khuri FR. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. *Cancer* 2014;120:3940-3951. PMID: 25103371
36. Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, **Harvey RD**, El-Rayes BF, Flowers CR. Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. *Clin Colorectal Cancer* 2014;13:219-225. PMID: 25306485
37. Soliman HH, Jackson E, Neuger T, Dees EC, **Harvey RD**, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. *Oncotarget* 2014;5:8136-8146. PMID: 25327557
38. Singh K, Stempora L, **Harvey RD**, Kirk AD, Larsen CP, Blazar BR, Kean LS. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. *Am J Transplant* 2014;14:2691-2693. PMID: 25359003
39. Barbee MS, Nooka A, Kaufman JL, Kim S, Chen Z, Heffner LT Jr, Lonial S, **Harvey RD**. Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. *Cancer* 2014 Nov 6. doi: 10.1002/cncr.29136. [Epub ahead of print]. PMID: 25377852.
40. Pentz RD, Hendershot KA, Wall L, White TE, Peterson SK, Thomas CB, McCormick J, Green MJ, Lewis C, Farmer ZL, Hlubocky FJ, Dossul T, Dixon MD, Liu Y, Switchenko JM, Salvador C,

- Owonikoko TK, **Harvey RD**, Khuri FR. Development and testing of a tool to assess patient preferences for phase I clinical trial participation. *Psychooncology* 2014 Dec 19. doi: 10.1002/pon.3731. [Epub ahead of print]. PMID: 25530552.
41. McKibbin T, **Donald Harvey R**, Saba NF. Pre-medications for cetuximab induced infusion reactions – commentary. *Oral Oncology* 2014 Dec;50(12):e71. doi: 10.1016/j.oraloncology.2014.08.009. PMID: 25223595.
  42. Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, Chen Z, Rogatko A, Tighiouart M, **Harvey RD**, Kim S, Saba NF, Pickens A, Behera M, Fu R, Rossi M, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR. A translational, pharmacokinetic and pharmacodynamic phase IB clinical study of everolimus in resectable non-small cell lung cancer. *Clin Cancer Res* 2015 Feb 11. pii: clincanres.1998.2014. [Epub ahead of print]. PMID: 25673697.
  43. Baz R, Lin HM, Hui AM, **Harvey RD**, Colson K, Gallop K, Swinburn P, Laubach J, Berg D, Richardson P. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. *Support Care Cancer*. 2015 Feb 24. [Epub ahead of print]. PMID: 25708126.
  44. **Harvey RD**. Adverse event recognition and management in practice and on clinical trials: Translating the Common Terminology Criteria for Adverse Events (CTCAE) (editorial). *Journal of Hematology Oncology Pharmacy*. 2015;5:6-7.
  45. Jagirdar N, **Harvey RD**, Nooka A, Flowers C, Kaufman J, Lonial S, Lechowicz MJ, Langston A, Lipscomb C, Gaylor C, Waller EK. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. *Transfusion* 2015. Sep 2. doi: 10.1111/trf.13186. [Epub ahead of print]. PMID: 26331348.
  46. Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel H, Berger AJ, Burke K, Mulligan G, Dezube BJ, **Harvey RD**. Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors. *Clin Cancer Res*. 2015 Sep 30. pii: clincanres.1338.2015. [Epub ahead of print]. PMID: 26423795
  47. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, **Harvey RD**, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma. *Clin Cancer Res* 2015 Nov 11. [Epub ahead of print]. PMID: 26561559
  48. Olszanski AJ, Smith DC, Camacho LH, Thompson J, Ramalingam SS, **Harvey RD**, Campos L, Ferry D, Tang S, Gao L, Safran H. Electrocardiographic characterization of ramucirumab on the corrected QT interval in a phase II study of patients with advanced solid tumors. *Oncologist* 2016 Mar 16. pii: theoncologist.2015-0467. [Epub ahead of print]. PMID 26984445.
  49. Lawson J, Switchenko JM, McKibbin T, **Harvey RD**. Impact of isotope dilution mass spectrometry (IDMS) standardization on carboplatin dose and adverse events. *Pharmacotherapy* 2016 Apr 30. doi: 10.1002/phar.1759. [Epub ahead of print]. PMID 27130286.
  50. **Harvey RD**. Calcium and cancer: Of evil humors and innocent bystanders. *J Oncol Pract* 2016 May;12(5):433-4. doi: 10.1200/JOP.2016.012385. PMID 27170691.
  51. Gupta N, Hanley MJ, **Harvey RD**, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrisnan K, Chari A. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. *Br J Haematol* 2016;174:748-759. PMID 27196567.



52. Mita MM, Nemunaitis J, Grilley-Olson J, El-Rayes B, Bekaii-Saab T, **Harvey RD**, Marshall J, Zhang X, Strout V. Phase 1 study of CEP-37250/KHK2804, a tumor-specific anti-glycoconjugate monoclonal antibody, in patients with advanced solid tumors. *Target Oncol* 2016;11:807-814. PMID: 27457707
53. Beardslee TJ, **Harvey RD**. Precision, accuracy, and resolution – Dose selection of oral anticancer agents. *Cancer* 2016 Aug 15. doi: 10.1002/cncr.30273. [Epub ahead of print]. PMID: 27526184
54. Wu B, Lewis LD, **Harvey RD**, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML. A pharmacokinetic and safety study of trebananib, a Fc-fusion peptibody, in patients with advanced solid tumors and varying degrees of renal dysfunction. *Clin Pharmacol Ther* 2017 Jan 11. doi: 10.1002/cpt.617. [Epub ahead of print]. PMID: 28074547
55. Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, **Harvey RD**, Venkatakrishnan K. Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labeling. *Clin Pharmacokinet* 2017 Mar 13. doi: 10.1007/s40262-017-0526-4. [Epub ahead of print] PMID: 28290121
56. Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, **Harvey RD**, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. *Br J Cancer* 2017 Oct 3. doi: 10.1038/bjc.2017.330. [Epub ahead of print] PMID: 28972963.
57. Lichtman SM, **Harvey RD**, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. *J Clin Oncol* 2017 Oct 2;JCO2017744102. doi: 10.1200/JCO.2017.74.4102. [Epub ahead of print] PMID: 28968172.
58. Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Yang JC, Bui K, Weilert D, **Harvey RD**. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. *Br J Clin Pharmacol* 2018 Jan 30 doi: 10.1111/bcp.13534. [Epub ahead of print] PMID: 29381826
59. Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, **Harvey RD\***, Schilsky RL\* (co-senior authors). American Society of Clinical Oncology Statement: Biosimilars in Oncology. *J Clin Oncol* 2018 Feb 14 JCO2017774893. doi: 10.1200/JCO.2017.77.4893.[Epub ahead of print] PMID: 29443651.
60. Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, **Harvey RD**, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. *J Clin Oncol* 2018 Mar 28; JCO2017764381. doi: 10.1200/JCO.2017.76.4381. [Epub ahead of print] PMID 29590007
61. Lockhart AC, Bauer TM, Aggarwal C, Lee CB, **Harvey RD**, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. *Invest New Drugs*. 2018 May 21. doi: 10.1007/s10637-018-0610-0. [Epub ahead of print] PMID: 29781056
62. Owonikoko TK, Busari AK, Kim S, Chen Z, Akintayo A, Lewis C, Carthon BC, Alese OB, El-Rayes BF, Ramalingam SS, **Harvey RD**. Race-, age-, and gender-based characteristics and toxicities of targeted therapies on phase I trials. *Oncology* 2018 Jun 18:1-9. doi: 10.1159/000488763. [Epub ahead of print] PMID: 29913438

63. **Harvey RD**, Aransay NR, Isambert N, Lee JS, Arkenau T, Vansteenkiste J, Dickinson PA, Bui K, Weilert D, So K, Thomas K, Vishwanathan K, Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. *Br J Clin Pharmacol* 2018; Sep 1. doi: 10.1111/bcp.13753. [Epub ahead of print] PMID: 30171779
64. Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, **Harvey RD**, Piantadosi S, Bertagnoli M, Schrag D, Schilsky RL. Accelerating anticancer drug development: Opportunities and tradeoffs. *Nat Rev Clin Oncol* 2018 Oct 1. doi: 10.1038/s41571-018-0102-3. [Epub ahead of print]. PMID: 30275514
65. Chehab S, Zhang C, Panjic EH, Chen Z, Kaufman JL, Lonial S, Nooka A, **Harvey RD**. Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. *Cancer* 2018 Oct 10 doi: 10.1002/cncr.31746. [Epub ahead of print]. PMID: 30303526
66. Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, **Harvey RD**. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. *Cancer* 2018 Oct 17. doi: 10.1002/cncr.31778. [Epub ahead of print] PMID: 30329148
67. Ou Y, Xu Y, Gore L, **Harvey RD**, Mita A, Papadopoulos KP, Wang Z, Cutler RE Jr, Pinchasik DE, Tsimberidou AM. Physiologically-based pharmacokinetic modeling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. *Br J Clin Pharmacol* 2018 Nov 14. doi: 10.1111/bcp.13817. [Epub ahead of print] PMID: 30428505
68. Kaufman JL, Mina R, Jakubowiak TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, **Harvey RD**, Lonial S. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. *Blood Cancer J* 2019 Jan 4;9(1):3. doi: 10.1038/s41408-018-0154-8. PMID: 30610196
69. Cook JW, McGrath MK, Dixon MD, Switchenko JM, **Harvey RD\***, Pentz RD\* (co-senior authors). Academic oncology clinicians' understanding of biosimilars and information needed before prescribing. *Ther Adv Med Oncol* 2019 Jan 6;11:1758835918818335. doi: 10.1177/1758835918818335. eCollection 2019. PMID: 30671144.
70. Saba N, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, Chen Z, Goff L, Cardin D, Lambright E, Nesbitt J, Krasinskas A, Higgins K, **Harvey RD**, Owonikoko T, Ramalingam SS, Shin DM, Beitler JJ, El-Rayes BF, Salaria S, El-Rifai W, Landry J, Chakravarthy AB. Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer. *Am J Clin Oncol* 2019 Feb 15. doi: 10.1097/COC.0000000000000524. [Epub ahead of print]. PMID: 30789414.
71. Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrisnan K, **Harvey RD**. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. *Br J Clin Pharmacol* 2019 Mar 7. doi: 10.1111/bcp.13915.[Epub ahead of print]. PMID: 30845347.
72. Grande E, **Harvey RD**, You B, Feliu Battle J, Galbraith H, Sarantopoulos J, Ramalingam SS, Mann H, So K, Johnson M, Vishwanathan K. Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment. *J Pharmacol Exp Ther* 2019 Mar 14. pii: jpet.118.255919. doi: 10.1124/jpet.118.255919. [Epub ahead of print]. PMID: 30872388.

73. **Harvey RD**, Zhang C, Lonial S, Kaufman JL, Chen Z. Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. *Cancer* 2019 Mar 28. doi: 10.1002/cncr.32080. [Epub ahead of print]. PMID: 30919409.
74. Shteamer JW, **Harvey RD**, Spektor B, Curseen K, Egan K, Chen Z, Gillespie TW, Sniecinski RM, Singh V. Safety of intranasal ketamine for reducing uncontrolled cancer-related pain: Protocol of a phase I/II clinical trial. *JMIR Res Proto* 2019 Apr 30; Apr 30;8(4):e12125. doi: 10.2196/12125. PMID: 31038469.
75. Mimche SM, Lee CM, Liu KH, Mimche PN, **Harvey RD**, Murphy TJ, Nyagode BA, Jones DP, Lamb TJ, Morgan ET. A non-lethal malarial infection results in reduced drug metabolizing enzyme expression and drug clearance in mice. *Malar J*. 2019 Jul 12;18(1):234. doi: 10.1186/s12936-019-2860-5. PubMed PMID: 31299982; PubMed Central PMCID: PMC6624958.
76. Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Shaib WL, Alese OB, Steuer CE, Wu C, Lawson DH, Kudchadkar R, Master VA, El-Rayes B, Ramalingam SS, Owonikoko TK, **Harvey RD**. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. *BMC Cancer*. 2019 Aug 29;19(1):857. doi: 10.1186/s12885-019-6073-7. PubMed PMID: 31464611; PubMed Central PMCID: PMC6716879.
77. Vishwanathan K, Cantarini M, So K, Masson E, Fetterolf J, Ramalingam SS, **Donald Harvey R**. Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer. *Clin Transl Sci*. 2019 Sep 9;. doi: 10.1111/cts.12688. [Epub ahead of print] PubMed PMID: 31498564.

b. Review Articles:

1. **Harvey RD**, Lindley C. Serotonin antagonists: an update. *Cancer Pract*. 1998;6:133-135. PMID: 9573914
2. Ewend MG, Carey LA, Morris DE, **Harvey RD**, Hensing TA. Brain metastases. *Curr Treat Options Oncol* 2001;2:537-547. PMID: 12057099
3. **Harvey RD 3<sup>rd</sup>**. Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. Introduction. *Pharmacotherapy* 2005;25:71S-72S. PMID: 16229676
4. **Harvey RD 3<sup>rd</sup>**. The patient: emerging clinical applications of intravenous immunoglobulin. *Pharmacotherapy* 2005;25:85S-93S. PMID: 16229679
5. Kempton CL, **Harvey RD 3<sup>rd</sup>**, Roberts HR. Novel therapeutic agents in the management of hemorrhage and thrombosis. *Cardiovasc Hematol Agents Med Chem* 2006;4:319-334. PMID: 17073609
6. **Harvey RD**, Lonial S. PI3 Kinase/Akt pathway as a therapeutic target in multiple myeloma. *Future Oncol* 2007;3:639-647. PMID: 18041916
7. Adams VR, **Harvey RD**. Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology. *Am J Health-Syst Pharm* 2010;67:(1 Suppl 1): S3-9. PMID: 20044377
8. **Harvey RD**, Fausel CA. Iron overload in myelodysplastic syndromes. Introduction. *Am J Health-Syst Pharm* 2010;67:(7 Suppl 2):S2. PMID: 20332502

9. **Harvey RD.** Myelodysplastic syndromes and the role of iron overload. *Am J Health-Syst Pharm* 2010;67:(7 Suppl 2):S3-9. PMID: 20332503
10. **Harvey RD.** Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer. *Clin Pharmacol Ther* 2014;96:214-223. PMID: 24690569
11. **Harvey RD.** Incidence and Management of Adverse Events in Patients with Relapsed and/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib. *Clin Pharmacol* 2014;8:87-96. PMID: 24855395
12. **Harvey RD, Morgan ET.** Cancer, inflammation, and therapy: Effects on cytochrome P450-mediated drug metabolism and implications for novel immunotherapeutic agents. *Clin Pharmacol Ther* 2014;96:449-457. PMID: 24987833
13. Richardson PG, **Harvey RD**, Laubach JP, Moreau P, Lonial S, San-Miguel JF. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: Pharmacology and clinical outcomes. *Expert Rev Clin Pharmacol* 2015 Oct 26:1-14. [Epub ahead of print]. PMID: 26503877
14. Howard SC, McCormick J, Pui CH, Buddington RK, **Harvey RD.** Preventing and managing toxicities of high-dose methotrexate. *Oncologist* 2016;21:1471-1482 PMID: 27496039
15. **Harvey RD.** Science of biosimilars. *J Oncol Pract* 2017; Sep;13(9\_suppl):17s-23s. doi: 10.1200/JOP.2017.026062. PMID: 28898589
16. Singh V, Gillespie TW, **Harvey RD.** Intranasal ketamine and its potential role in cancer-related pain. *Pharmacotherapy* 2018; Feb 3. doi: 10.1002/phar.2090. [Epub ahead of print]. PMID: 29396996
17. Lyman GH, Zon R, **Harvey RD**, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. *N Engl J Med* 2018 May 24;378(21):2036-2044. doi: 10.1056/NEJMhle1800125. PMID: 29791832
18. Moore DC, Arnall JR, **Harvey RD.** Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma. *J Oncol Pharm Pract* 2018 Jul 31:1078155218788706. doi: 10.1177/1078155218788706. [Epub ahead of print]. PMID: 30060709
19. Gupta N, Hanley MJ, Xia C, Labotka R, **Harvey RD**, Venkatakrishnan K. Clinical pharmacology of ixazomib: The first oral proteasome inhibitor. *Clin Pharmacokinet* 2018 Aug 17. doi: 10.1007/s40262-018-0702-1. [Epub ahead of print] Review. PMID: 30117017

c. Book Chapters:

1. **Harvey RD.** Chronic Myelogenous Leukemia. In Schwinghammer TL, ed. *Pharmacotherapy Casebook: A Patient-Focused Approach*, 5<sup>th</sup> ed. Stamford, Connecticut: Appleton and Lange, 2002:374-377.
2. **Harvey RD.** Sickle Cell Anemia. In Schwinghammer TL, ed. *Pharmacotherapy Casebook: A Patient-Focused Approach*. 5<sup>th</sup> ed. Stamford, Connecticut: Appleton and Lange, 2002:282-284.
3. **Harvey RD, Valgus JM.** Hematologic Malignancies. In Koda-Kimble, et al., eds. *Applied Therapeutics: The Clinical Use of Drugs*. 8<sup>th</sup> ed. Philadelphia: Lippincott, Williams, and Wilkins, 2004:90-1 – 90-42.

4. Haines ST, Dowling T, **Harvey RD**. Warfarin. In Burton, et al., eds. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring, 4<sup>th</sup> ed. Philadelphia: Lippincott, Williams, and Wilkins, 2005:715-751.
5. **Harvey RD**, Walko CM. Chronic Myelogenous Leukemia. In Schwinghammer TL, ed. Pharmacotherapy Casebook: A Patient-Focused Approach, 6<sup>th</sup> ed. New York: McGraw-Hill, 2005:382-384.
6. Walko CM, **Harvey RD**. Sickle Cell Anemia. In Schwinghammer TL, ed. Pharmacotherapy Casebook: A Patient-Focused Approach, 6<sup>th</sup> ed. New York: McGraw-Hill, 2004:284-287.
7. **Harvey RD**, Brundage D. Hemophilias and Thrombophilias. In: Schumock G, Brundage D, Richardson M, et al, eds. Pharmacotherapy Self-Assessment Program, 5<sup>th</sup> ed. Hematology and Oncology. Kansas City, MO: American College of Clinical Pharmacy, 2006: 17-36.
8. Valgus JM, Haas M, **Harvey RD**. Hematologic Malignancies. In Koda-Kimble, et al., eds. Applied Therapeutics: The Clinical Use of Drugs. 9<sup>th</sup> ed. Philadelphia: Lippincott, Williams, and Wilkins, 2008: 90-1 – 90-44.
9. **Harvey D**, Silberman J, Lonial S. The PI3 Kinase/Akt Pathway as a Therapeutic Target in Multiple Myeloma. In: Lonial S, ed. Contemporary Hematology: Myeloma Therapy. 1<sup>st</sup> ed. Totowa, NJ: Humana Press, 2008:309-322.
10. **Harvey RD**, Khuri FR. Cytotoxic Chemotherapy. In Ades T, Brawley OW, Gansler T, et al. (Eds.), The American Cancer Society's Principles of Oncology: Prevention to Survivorship. Atlanta, GA: Wiley Blackwell, 2017:220-235.

d. Published Abstracts:

1. Choksi NY, Hussain A, Myers AM, Owens CE, **Harvey RD**, Wyrick SD, Baldessarini RJ, Booth RG. Stimulation of brain cAMP and dopamine synthesis by adenosine A<sub>2</sub> and  $\sigma_3$  agonists. Society for Neuroscience Abstracts, Volume 20, 1994.
2. Choksi NY, Hussain A, Owens CE, Myers AM, **Harvey RD**, Baldessarini RJ, Wyrick SD, Booth RG. Adenosine A<sub>2</sub> and PAT- $\sigma_3$  agonists affect adenylyl cyclase activity and dopamine synthesis in rat brain (abstract). Presented at the North Carolina Society for Neuroscience Spring Meeting, May 1994.
3. Valgus JM, Lindley C, **Harvey RD**, Poole ME, Shord SS, Bernard SA. Incidence and duration of oxaliplatin-induced nausea and vomiting. Proc Am Soc Clin Oncol 2001;20 1624a.
4. Escobar M, **Harvey RD**. Experience with the use of recombinant factor VIIa in a university hospital. Blood 2001; 101: 3902a.
5. Shea TC, Serody J, Gabriel D, Comeau T, **Harvey D**, Irons R, Morris D. High relapse rate following alemtuzumab use in allogeneic transplants for myeloid hematologic malignancies. Blood 2004; 104: 1826a.
6. Comeau T, Shea T, Gabriel D, Morris D, Irons R, **Harvey D**, Serody J. BK Viruria in patients undergoing allogeneic hematopoietic stem cell transplantation: Increased incidence in patients receiving alemtuzumab (ALEM) as conditioning therapy and lack of efficacy of cidofovir. Blood 2004; 104: 3160a.
7. **Harvey RD**, Shea T, Walko C, Krasnov C, Patel L, Serody J, Gabriel D, Comeau T, Lindley C. Intravenous busulfan test dose clearance comparison with first and thirteenth dose systemic exposure in allogeneic bone marrow transplant recipients. J Clin Oncol 2005; 23: 6658a.

8. Walko CM, Lindley CM, Collins J, Krasnov C, **Harvey RD**, Gabriel DA, Serody J, Comeau T, Shea TC. 90 hour continuous intravenous busulfan infusion: PK and test dose predictability in allogeneic bone marrow transplant patients. *J Clin Oncol* 2005; 23: 6652a.
9. Lonial S, Francis D, Karanes C, Trudel S, Reece DE, Krishnan A, Buacharern M, Smith R, Zaman F, Gul E, Dollard AM, **Harvey D**, Kaufman J. A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma. *Blood* 2008; 112: 3706a.
10. Wierda WG, Chen R, Plunkett W, Coutre S, Badros AZ, Popplewell L, Siegel D, Sinha R, **Harvey D**, Fox J, Mahadocon K, Kegley P, Bolton MG. A phase 1 trial of SNS-032, a potent and specific CDK 2, 7 and 9 inhibitor, in chronic lymphocytic leukemia and multiple myeloma. *Blood* 2008; 112: 3178a.
11. Yoon Y, Wei L, Zhang Z, **Harvey RD**, Park JC, Olson JJ, Hu X, Shim H. Using proton MRS to predict responses of SAHA treatment in glioblastoma [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3993
12. Pentz RD, Khuri F, Kauh J, Owonikoko T, White MM, **Harvey RD**. Proportion of subjects with an ethically acceptable reason for enrolling in a phase I trial. *J Clin Oncol* 2009; 27: 2512a.
13. Kauh JS, Cohen R, Clarke JW, **Harvey R**, Mulligan G, Venkatakrishnan K, Berger A, Smith PG, Petruzelli L, Sarantopoulos J. Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin. *J Clin Oncol* 2009; 27: 2562a.
14. Lonial S, Francis D, Karanes C, Trudel S, Dollard A, **Harvey D**, Kaufman J. A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma. *J Clin Oncol* 2009; 27: 8597a.
15. Khuri FR, **Harvey RD**, Saba NF, Owonikoko TK, Kauh J, Shin DM, Sun SY, Browning KM, Tighiouart M, Ramalingam SS. Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study. *J Clin Oncol* 2009; 27: 8060a.
16. Lonial S, **Harvey RD**, Francis D, Gul E, Jagannath S, Farag S, Hoth D, Frumento R, Garlich JR, Trudel S. Preliminary results of a phase I study of the pan-PI3 kinase inhibitor SF1126 in patients with relapsed and refractory myeloma. *Blood* 2009; 114: 3879a.
17. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Patterson M, **Harvey D**, Berger AJ, McDonald A, Mulligan G, Petruzzelli L, Pickard MD, Smith PG, Venkatakrishnan K, Lonial S. Phase 1 dose-escalation study of MLN4924, a novel NAE inhibitor, in patients with multiple myeloma and non-Hodgkin lymphoma. *Blood* 2009; 114: 1854a
18. Jones SF, Cohen RB, Bendell JC, Denlinger CS, **Harvey RD**, Parasuraman S, Chi X, Scholz C, Wyant T, Kauh J. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study. *J Clin Oncol* 2010; 28: 3081a.
19. Kauh JS, **Harvey RD**, Lawson DH, Owonikoko TK, Tighiouart M, Ramalingam SS, Shin DM, Lewis CM, El-Rayes BF, Khuri FR. Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. *J Clin Oncol* 2010; 28: 2538a.
20. **Harvey RD**, Kauh JS, Ramalingam SS, Lewis CM, Chen Z, Lonial S, Blount IC, Shin DM, Khuri FR, Owonikoko TK. Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. *J Clin Oncol* 2010; 28: 5589a.

21. Kaufman JL, Shah JJ, Laubach JP, Heffner L, Francis D, **Harvey RD**, Lewis C, Tighiouart M, Richardson P, Orlowski RZ, Lonial S. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): Initial results of a phase 1 study. *Blood* 2010; 116: 3034a.
22. Shah JJ, **Harvey RD**, O'Connor OA, Jakubowiak AJ, Smith MR, Orlowski RZ, Mulligan G, Smith PG, Pickard MD, Dezube BJ, Lonial S. Phase 1 dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a nedd-8-activating enzyme inhibitor, in patients with relapsed and/or refractory multiple myeloma or lymphoma. *Blood* 2010; 116: 2801a.
23. Kauh JS, Shapiro G, Cohen RB, Clark JW, **Harvey RD**, Cleary JM, Mahalingam D, Kuan S, McDonald A, Berger A, Dezube B, Sarantopoulos J. MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules. *J Clin Oncol* 2011; 29: 3013a.
24. Pentz RD, Farmer ZL, Green ML, Daugherty C, Hlubocky FJ, Peterson SK, Sun CC, Lewis CM, Owonikoko TK, Khuri FR, **Harvey RD**. Assessing patients' values when standard-of-care options are exhausted. *J Clin Oncol* 2011; 29: 9108a.
25. **Harvey RD**, Lewis CM, Kauh JS, Owonikoko TS, Akintayo A, Karol M, Teofilovici F, Khuri FR, Ramalingam SS. A phase 1 and pharmacokinetic study of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel in patients with advanced solid tumor malignancies. *ESMO* 2011, abstract 1230.
26. Lonial S, Cohen A, Zonder J, Bensinger WI, Kaufman JL, Orlowski RZ, **Harvey RD**, Alexanian R, Thomas SK, Weber D, Walker D, Hilder B, Ptaszynski A, Shah JJ. The novel KSP inhibitor ARRY-520 demonstrates single-agent activity in refractory myeloma: Results from a phase 2 trial in patients with relapsed/refractory multiple myeloma (MM). *Blood* 2011; 118: 2935a.
27. Shah JJ, Zonder J, Cohen A, Orlowski RZ, Alexanian R, Thomas SK, Weber D, Kaufman JL, **Harvey RD**, Walker D, Litwiler K, Karan S, Hilder B, Ptaszynski AM, Lonial S. ARRY-520 shows durable responses in patients with relapsed/refractory multiple myeloma in a phase 1 dose-escalation study. *Blood* 2011; 118: 1860a.
28. Nooka AJ, Muppidi S, **Harvey RD**, Kaufman JL, Langston A, Lewis C, Boise LH, Flowers CR, Lonial S. A predictive model of overall survival (OS) for patients with relapsed/refractory multiple myeloma (MM) enrolling in phase I clinical trials. *Blood* 2011; 118: 3954a.
29. **Harvey RD**, Lonial S, Renfro H, Sinha R, Flowers CR, Lechowicz MJ, Khoury HJ, Langston A, Waller EK, Kaufman JL. Temporal changes in plerixafor administration do not impact hematopoietic stem cell mobilization efficacy: Results of a prospective clinical trial. *Blood* 2011; 118: 2988a.
30. **Harvey RD**, Jacobus SJ, Rajkumar SV, Greipp PR, Lonial S. Renal function measures improve on lenalidomide and dexamethasone and compete with patient characteristics to predict lenalidomide dose density and hematologic toxicity: An E4A03 analysis. *Blood* 2011; 118: 1882a.
31. Owonikoko TK, **Harvey RD**, Kauh JS, Lewis CM, Hossain MS, Akintayo AO, Merriewether AR, Chen Z, Hawk NN, Saba NF, Harris W, Shin DM, El-Rayes BF, Huang C, Lonial S, Lawson DH, Khuri FR, Waller EK, Ramalingam SS. A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies. *J Clin Oncol* 2012; 30: 2576a.
32. Appleman LJ, Beumer JH, Jiang Y, Puhalla S, Lin Y, Owonikoko TK, **Harvey RD**, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Kiesel B, Chu E, Shepherd SP, Giranda VL, Chen

- AP, Belani CP, Ramalingam SS. A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies. *J Clin Oncol* 2012; 30: 3049a.
33. Shim H, Voloschin AD, Wei L, Hwang SN, Miller AH, Guo Y, Brat D, Holder CA, Read WL, Kopcewicz K, **Harvey RD**, Barker P, Shu HG, Hu XP, Olson JJ. Using proton MRSI to predict response to vorinostat treatment in recurrent GBM. *J Clin Oncol* 2012; 30: 3055a.
  34. Kauh JS, **Harvey RD**, Owonikoko TK, El-Rayes BF, Shin DM, Murali S, Lewis CM, Karol MD, Teofilovici F, Du Y, Fu H, Khuri FR, Ramalingam SS. A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies. *J Clin Oncol* 2012; 30: 3094a.
  35. Shah JJ, Zonder JA, Cohen A, Bensinger W, Kaufman JL, Orlowski RZ, **Harvey RD**, Abidi MH, Thomas SK, Walker D, Hilder B, Ptaszynski AM, Lonial S. The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: Results from a phase 2 study. *Blood* 2012; 120: 449a.
  36. Tiwari D, Horan J, Langston A, Qayed M, Carr J, Renfro H, Cynthia C, Khoury HJ, Robertson J, **Harvey RD**, Mehta A, Waller EK, Kean LS. A first-in-disease trial of in vivo costimulation blockade for acute GvHD prevention: The addition of abatacept to standard GvHD prophylaxis controls early CD4+ T cell proliferation and is associated with low rates of severe acute GvHD. *Blood* 2012; 120: 741a.
  37. Kaufman JL, Shah JJ, Laubach JP, Mitchell AR, Sharp C, Lewis C, **Harvey RD**, Gleason C, Casbourne D, Nooka AK, Heffner LT, Richardson PG, Orlowski RZ, Lonial S. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): Results of a phase 1 study. *Blood* 2012; 120: 336a.
  38. Kauh JS, **Harvey RD**, Owonikoko TK, El-Rayes BF, Shin DM, Murali S, Lewis CM, Karol MD, Teofilovici F, Du Y, Fu H, Khuri FR, Ramalingam SS. A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies. *J Clin Oncol* 2012; 30: 3094a.
  39. Jackson E, Dees EC, Kauh JS, **Harvey RD**, Neuger A, Lush R, Antonia SJ, Minton SE, Ismail-Kahn R, Han HS, Vahanian NN, Ramsey WJ, Link CJ, Streicher H, Sullivan D, Soliman HH. A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. *J Clin Oncol* 2013; 31: 3026a.
  40. Saba NF, Kono SA, Mendel JR, Hurwitz SJ, Owonikoko TK, Lewis CM, **Harvey D**, Rogerio JW, Chen Z, Wadsworth T, El-Deiry M, Chen AY, Higgins K, Ramalingam SS, Beitler JJ, Shin DM, Khuri FR. Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study. *J Clin Oncol* 2013; 31: 6083a.
  41. Kaufman J, Zimmerman T, Jakubowiak A, Rosenbaum C, Lewis C, **Harvey D**, Nooka A, Heffner L, Lonial S. Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: A multicenter MMRC clinical trial. *Haematologica* 2013; 98: suppl 1: P771.
  42. Shah N, Kaufman J, Langston A, Waller E, **Harvey R**, Lonial S, Nooka A. Eliminating the need for 24-hour urine studies in phase 1 myeloma patients. *Haematologica* 2013; 98: suppl 1: B1498.
  43. **Harvey RD**, Lewis CM, Pillai R, Lawson D, Ramalingam SS, Morgan ET. Novel Immunotherapeutics and Concurrent CYP Substrate Use in Advanced Cancer. *J Oncol Pharm Pract* 2014; 20 3(supplement): abstract 19.



44. Sarantopoulos J, Gordon MS, **Harvey RD**, Sankhala KK, Malik L, Mahalingam D, Owonikoko TK, Lewis CM, Payumo F, Miller J, Powell C, Weng Z, Komarnitsky PK, Ramalingam SS. First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors. *J Clin Oncol* 2014; 11113a.
45. Goldstein DA, Chen Q, Howard DH, Lipscomb J, Ayer T, **Harvey D**, El-Rayes BF, Flowers C. Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC). *J Clin Oncol* 2014; 6527a.
46. Kaufman J, Zimmerman T, Rosenbaum CA, Nooka AK, Heffner LT, **Harvey RD**, Gleason CG, Lewis C, Sharp C, Barron KW, Lonial S. Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: A Multiple Myeloma Research Consortium (MMRC) clinical trial. *Blood* 2014; 124: 32a.
47. Matous J, Siegel DS, Lonial S, **Harvey RD**, Kasserra C, Li Y, Chen M, Doerr T, Sternas L, Zaki MH, Jacques C, Shah JJ. MM-008: A phase I trial evaluating pharmacokinetics and tolerability of pomalidomide with low dose dexamethasone in patients with relapsed or refractory and refractory multiple myeloma and renal impairment. *Blood* 2014;124:4730a.
48. Divino V, Dekoven M, Wang W, Kleinrock M, **Harvey RD**, Wade RL, Kaura S. The budget impact of orphan drugs in the US: A 2007-2013 MIDAS sales data analysis. *Blood* 2014;124:736a.
49. Gupta N, Hanley MJ, **Harvey RD**, Badros AZ, Lipe BC, Kukreti V, Berdeja JG, Yang H, Hui A-M, Zhang X, Venkatakrishnan K, Chari A. Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis. *Blood* 2015; 126: 336a.
50. **Harvey RD**, Chen YJ, Lethen J, Mahue M. Relationship of carfilzomib dosing and duration of therapy (DOT) in patients with relapsed and refractory multiple myeloma (RRMM). *Blood* 2015;126:453a
51. Faessel HM, **Harvey RD**, Lockhart AC, Bauer TM, Wang L, Sedarati F, Santillana S, Nemunaitis JJ. Drug-drug interaction (DDI) study between the investigational NAE inhibitor pevonedistat (TAK-924) and fluconazole or itraconazole in patients with advanced solid tumors. *Clin Pharmacol Ther* 2016: PII084
52. **Harvey RD**, Gore L, Wang D, Mita A, Sharma S, Nemunaitis J, Papadopoulos K, Pinchasik D, Ou Y, Demirhan E, Cutler RE, Tsimberidou AM. A phase I study to assess food effect on oprozomib in patients with advanced malignancies. *Clin Pharmacol Ther* 2016: PII-090
53. Tsimberidou AM, Ou Y, Xu Y, Wang Z, **Harvey RD**, Mita A, Sharma S, Papadopoulos K, Wang D, Pinchasik D, Demirhan E, Cutler RE, Gore L. A phase I study of oprozomib to assess drug-drug interaction with midazolam patients with advanced malignancies. *Clin Pharmacol Ther* 2016: PII-096
54. Vishwanathan K, Cantarini M, So K, Masson E, Fetterolf J, Patel H, Morgan E, Ramalingam S, **Harvey D**. Impact of disease and treatment response in DDI studies: AZD9291 and simvastatin in advanced non-small cell lung cancer (ANSCLC). *Clin Pharmacol Ther* 2016: LB-003.
55. Bauer TM, **Harvey RD**, Lee CB, Aggarwal C, Cohen RB, Sedarati F, Teng Z, Faessel HM, Dash A, Dezube BJ, Santillana S, Dowlati A, Lockhart AC. Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/Paclitaxel (Pac). *J Clin Oncol* 34, 2016 (suppl; abstr 2580)

56. Lassen UN, Ramalingam SS, Lopez JS, **Harvey RD**, Ameratunga M, de Hoon J, Losic N, Lisby S, Forssmann U, Vergote I. GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817). *J Clin Oncol* 35, 2017 (suppl; abstr TPS2605)
57. Bazhenova L, Gold PJ, **Harvey RD**, Spira AI, Nemunaitis J, Baranda JC, Gadgeel S. A Phase 1b study of PEGPH20 plus pembrolizumab in patients with selected hyaluronan-high solid tumors [abstract]. *Cancer Res* 2017;77(13 Suppl):Abstract nr CT032. doi:10.1158/1538-7445.AM2017-CT032
58. Dowlati A, Rugo HS, **Harvey RD**, Kudchadkar RR, Carvajal RD, Manji GA, Hamid O, Klempner SJ, Tang S, Yu D, Kauh JS, Schaer DA, Tate SC, Wesolowski R. A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors. *J Clin Oncol* 35, 2017 (suppl; abstr 2523)
59. Gordon MS, Shapiro G, Sarantopoulos J, Juric D, Lu B, Chen P, Connarn J, Le Bruchec Y, **Harvey RD**. A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST). *J Clin Oncol* 36, 2018 (suppl; abstr 2547)
60. **Harvey RD**, Kaufman JL, Heffner LT, Hofmeister CC, Dhodapkar MV, Lonial S, Nooka AK. Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction. *J Clin Oncol* 36, 2018 (suppl; abstr 80456)
61. Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Shaib WL, Alese OB, Pillai R, Steuer CE, Wu C, Lawson DH, Kudchadkar R, El-Rayes B, Master VA, Ramalingam S, Owonikoko TK, **Harvey RD**, Bilan MA. Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO) [abstract]. *Cancer Res* 2018;78(13 Suppl):Abstract nr 2607.

# Jeffery Neal Seymour



## WORK EXPERIENCE

- 2015-Present* Director of History & Collections, The National Civil War Naval Museum
- 2004-Present* Adjunct Professor, Columbus State University  
Duties include teaching United States History, Colonial to 1865 and 1865 to Present
- 2005-2015* Curator/Archivist/Historian, Port Columbus National Civil War Naval Museum  
Duties include, but not limited to, maintaining and cataloging the collections of the museum, archives, and library. I also routinely provide tours and a variety of programming for a wide variety of groups and educational levels.
- 2002-2007* Adjunct Professor, Chattahoochee Valley Community College  
*2014-2016* Duties included teaching classes in Early and Modern World History and United States History, Colonial to 1865 and 1865 to Present.
- 2007-2019* Reader for Advanced Placement U.S. History Exam, Educational Testing Services. Promoted to Table Leader in 2014. Promoted to Assistant Question Leader in 2018, which serves on the team that sets the grading rubric.
- 2008-2010* Online Adjunct Professor, American Military University  
Duties include teaching classes on the American Civil War and the American Revolution.
- 2004* Archivist, Montgomery County Historical Society  
Duties included acquiring, accessioning, preserving, and arranging material according to the needs of the society. The cataloging was done on PastPerfect software.
- 2004-2008* Visitor Services, Port Columbus National Civil War Naval Museum  
Duties include maintaining the ticket booth, gift shop, and preparing financial reports.
- Summer 2003* Archival Internship at the Tuskegee University National Center of Bioethics Archives and Museums  
Duties included accessioning, arranging and preserving material according to the needs of Tuskegee University.
- 2002-2003* Instructor, Freshman Experience, Auburn University  
Duties included teaching study skills at the collegiate level.
- 2001-2004* Tour Guide & Living Historian, Port Columbus National Civil War Naval Museum
- 2001-2003* Adjunct Professor, Southern Union State Community College  
Duties included teaching Early and Modern Western Civilization classes.
- 2001* Substitute Teacher, Troup County, Georgia Schools.

## EDUCATION

- 2015 M.A. Certificate, Archival Studies, Auburn University  
2006 ABD Status, PhD Program, History Auburn University  
2000 M.A., History Jacksonville State University  
Master's Thesis: *William C. Oates: Quintessential Bourbon Democrat or Unreconstructed Confederate*  
1998 B.A., History Jacksonville State University  
Graduated with honors

## STUDENT ACHIEVEMENTS

### Graduate:

Graduate Assistant, Margaret Cole Award, named outstanding Graduate Assistant of the Year, Jacksonville State University, 2001.

### Undergraduate:

Phi Alpha Theta History Honor Society, President; History Club, various offices held; Pinnacle Honor Society; Omicron Delta Kappa Honor Society; Model Arab League, Head Delegate; Phi Mu Alpha Professional Music Fraternity, various offices held; University Marching Band, section leader; Scholarship Pep Band member; various other music organizations.

## PROFESSIONAL ORGANIZATIONS

Organization of American Historians  
Southern Historical Society  
Society of Civil War Historians  
Society for Military History  
Georgia Historical Society  
Phi Alpha Theta  
Society of Georgia Archivists  
Georgia Association of Museums and Galleries  
Association of Registrars and Collections Specialists

## PANELS AND PAPERS

- Georgia Association of Museums and Galleries, January 2019, Panel Chair  
*Difficult History*  
National Civil War Naval Museum Symposium, July 2016, Organizer and Moderator  
*Wrecks, Recovery, and Conservation*  
Tampa Civil War Round Table, February 2016  
*Yes, Virginia, There was a Confederate Navy*  
Pensacola Civil War Round Table, Spring 2015  
*Confederate Ironclads*  
Georgia Tech Technology and the American Civil War, April 2014  
Panel on Curating Civil War Technology  
Society of Civil War Surgeons National Convention, March 2012  
Presentation: *The Autopsy of John Wilkes Booth*  
Keynote Address: *Civil War Naval Medicine: The Steam Engine Component*  
Ashantilly Center in Cooperation with the Georgia Humanities Council's Civil War Sesquicentennial Observation, February 2012  
*John McIntosh Kell: The "Luff"*  
National Infantry Museum Civil War Sesquicentennial Symposium, April 2011  
*William C. Oates as a Non-West Point Trained Officer*

Northwest Louisiana Civil War Round Table, October 2010  
*The Navies During the Civil War*

Low Country Civil War Round Table, May 2009  
*Raphael Semmes*

Georgia Association of Historians Annual Meeting, February 2009  
*The Mysterious Case of the Dahlonaga Diving Bell*

National Civil War Naval Museum Annual Symposium, November 2006  
*What Did You Know and When Did You Know It? The Story of the ORNs*

Georgia Association of Historians, April 2005  
Panel Chair for *On Georgia Waters: Some Influences on the War of 1861-1865 on Coastal Georgia*

Phi Alpha Theta Alabama State Convention, April 2003  
*Southern Capitalism: Lloyd G. Bowers and the Importing and Exporting Company of Georgia*

Alabama Historical Association, April 2000  
*William C. Oates: Politics During the Agrarian Revolt*

Phi Alpha Theta National Convention, December 1999  
*William C. Oates: Quintessential Bourbon Democrat or Unreconstructed Rebel?*

Southern Writers, Southern Writing, July 1999  
*The South and the Election of 1876*

Various public presentations for a variety of organizations and other public venues, which include public schools, professional, and other organizations, such as historical societies.

## **PUBLICATIONS**

### Articles:

*Civil War Navy*  
*National Civil War Naval Museum: A National Treasure* (Fall 2017)

*Port City Ram*  
Regular contributor to the quarterly newsletter of the NCWNM.

### Book Reviews:

*History: Reviews of New Books*  
Review of *A Confederate Biography: The Cruise of the CSS Shenandoah* (September 2017)

*H-Net for H-CivWar*  
Review of *Lincoln and His Admirals* by Craig Symonds (February 2010)  
Review of *My Dear Friend: The Civil War Letters of Alva Benjamin Spencer 3<sup>rd</sup> Georgia Regiment Company C* by Clyde G. Wiggins (January 2008)

*Nautical Research Journal*  
Review of *The Officers of the CSS Shenandoah* by Angus Curry (December 2006)

*Anniston Star*  
Review of *Confederate Homefront: Montgomery During the Civil War* by William Warren Rogers, Jr. (July 2000)

### Encyclopedia Articles

*Encyclopedia of the War of 1812*, ABC-Clio  
"Arthur Sinclair"  
"Melancthon Woolsey"

"Ropewalk"  
"USS New Orleans"  
*Encyclopedia of the Mexican War*, ABC-Clio  
"Blockade"  
*Encyclopedia of the Korean War*, ABC-Clio  
"Mine Warfare"  
*Gale Library of Daily Life: American Civil War*  
"Shipbuilding"

### **TELEVISION APPEARANCES AND PROFESSIONAL CONSULTATION**

- 2017 Started series of YouTube videos on the Port Columbus channel entitled *Curator's Corner*:
- Reproduction Blakely Rifle*
  - Museum Donations*
  - Pass Box Acquisition*
  - The Engines of the CSS Chattahoochee*
  - The CSS Jackson Fantail*
  - Exhibit Development*
  - Inside the CSS Jackson*
  - US Monitor Identification*
  - Paper Issues*
  - Why Is It So Dark In The Museum*
  - Cannon Conservation Project*
  - The VII in. Brooke Rifle and Markings*
- 2017 On-air expert and consultant for Two-Egg Productions documentary *CSS Chattahoochee*.
- 2016 Interviewed by various media outlets about the *CSS Georgia* project
- 2016 On-air expert for airing of Colonial Williamsburg's documentary about Civil War ironclads
- 2015 Interviewed by C-Span for the "Cities Tour" program on Columbus, GA
- 2013 Consultant on a documentary about Civil War ironclads produced by Colonial Williamsburg
- 2012 Consulting with various U.S. Army organizations at Fort Benning developing Officer Staff Rides, which include *The Battle of Mobile Bay* and *The Battle of Columbus*.
- 2012 Consultant and actor for documentary *Savannah In the Civil War*
- 2008 Interviewed by Channel 3 News Columbus, Georgia about the history of Independence Day. Aired July 4, 2008.
- 2007 Interviewed on *Georgia Traveler* about the National Civil War Naval Museum. Georgia Public Television
- 2006 Consultant for documentary entitled *The Last Ditch* about the Battle of Columbus. Georgia Public Television. The documentary is the winner of two regional Emmy Awards.

### **PROFESSIONAL SERVICE**

- 2019 Judge for National History Day for the State of Georgia
- 2011 Judge for National History Day for the State of Georgia
- 2009 Listserv Manager for Society of Georgia Archivists

# KIMBERLY SCOFI

## Summary

A dedicated nonprofit Executive Director with fifteen years of organizational leadership providing food, housing, and supportive services to a diverse population. Qualifications include development, and implementation of successful fundraising, marketing, and constituent programs with measurable growth year after year.

## Experience

**United Military Care / Marietta, GA / 07/2012 to Present**

**President|Executive Director**

- Built a successful statewide nonprofit serving military veterans and their families from the ground up, increasing program services to 8,000 clients annually.
- Developed marketing plans to include web site, and social media platforms highlighting the organization with growth to over 17,000 impressions statewide per outreach.
- Successfully networked and cultivated partnerships with professional sports teams, major corporations, and influential community affiliates generating awareness throughout state, and southeastern region.
- Created diverse revenue generating platforms to include major gifts, grants, and corporate giving to successfully reach fundraising goals.
- Recruited and trained diverse Board of Directors committed to the organizational cause.

**Operation Homefront - Georgia / Marietta, Georgia / 11/2007 to 06/2012**

**Executive Director**

- Created fundraising and marketing campaign for small independent chapter of a national organization expanding services from one military installation to statewide program coverage to include budget growth to over \$2MM annually.
- Built and trained staff from one to seven, and created a volunteer program with 423 registered volunteers.
- Participated in major market radio and television interviews on a weekly basis highlighting organization, and harnessing support.
- Promoted from Development Director to Executive Director following ten months of employment.

## Education

**Nonprofit Management**

**Northwestern University-Kellogg School of Nonprofit Management**

**Evanston, IL**

Leadership  
Board Governance  
Finance  
Marketing and Communications  
Impact Measurement

**Paralegal Studies**

**Kennesaw State University**

**Kennesaw, Georgia**

Criminal & Civil Law  
Legal Research & Writing  
Real Estate & Family Law

## Contact



## Skills

Nonprofit Leadership  
Compassionate  
Fundraising  
Marketing Web Social  
Strategic Planning  
Program Development  
Growth Change Management  
Business Administration  
Team Building Management  
Board Volunteer Development  
Public Speaking  
Volunteer Programs

## Activities And Honors

2018 Congressional Medal of Honor  
Foundation Civilian Honoree

- Current Activities:

American Legion Ladies Auxiliary  
Post 29

- Former Activities:

Honorary Commander (Military)  
Cobb Chamber of Commerce  
GA Chamber of Commerce  
Assoc of Fundraising Professionals  
National Assoc Professional  
Women  
Parent Teacher Student Assoc  
Speaker-National Day of Prayer  
Felony Victim Witness Protection  
Reserve Auxiliary Deputy SGT  
Sisters in Crime Atlanta

## Certifications

Advanced Grant Writing  
Change Leadership  
Branding  
Organizational Analysis

**RE: LETTER OF EMPLOYMENT OPPORTUNITIES**

Dear Human Resource Manager,

I am contacting you to explore employment opportunities with your organization for an open position with a progressive firm such as yours.

The accompanying resume will provide you with details regarding my background, experience, skills and abilities.

You will note that I have extensive experience in all aspects of the business industry particularly real estate, construction, sales, and management.

The outstanding ability to manage and motivate performance on an ongoing basis. Detail knowledge of residential property management, administrative duties, with solid communications skills relating to clients, customers, employees, and negotiating capabilities as well as other aspects of the industry.

During my years in this field I have gained proficient in all areas, and now I am anxious to put these skills to work of an organization which will reward a diligent and conscientious employee. I feel that your company is just such a place.

I am seeking a full time permanent position, which allows the use of my skills and people oriented qualities developed from previous employment. The ideal position would take advantage of my following assets.

- Self starter with out going personality who needs no supervision, and can think on my feet
- A good hard working loyal employee, and excellent coordinator, able to delegate workloads.
- Knowledge of apartment, residential, commercial management techniques and methods
- Excellent negotiating techniques, in depth knowledge of performance goals
- Excellent administration and organization skills
- Team player and the ability to work under high-pressure situations
- In depth knowledge of real estate, maintenance, construction and business
- Computer literate
- Hands on product experience.

At your convenience, I would like the opportunity to meet with you to discuss the goals and objectives of your organization and how my experience and abilities will assist in fulfilling them.

Sincerely,

Quinton Smith

QS/II



**QUINTON E. SMITH**

**Job Target: TO OBTAIN A RESPONSIBLE POSITON WHERE MY EXPERIENCE, ACCOMPLISHMENTS, AND PROFICIENCY WILL ALLOW ME THE OPPORTUNITY FOR GROWTH.**

**CAPABILITIES:** Self directed professional with a diverse background and comprehensive knowledge in real estate sales, acreage, farms, timberland, farm & construction equipment, estates, collectables, personal property of all kinds, in-depth knowledge of auction business.

- \* Successful in establishing and managing new business divestiture.
- \* Experience is highlighted with strong decision making, effective administration duties, motivation, training, solid negotiation and good leadership qualification in a professional manner.
- \* Communicative and organized, able to quickly grasp the business and objectives to prosperously enhance bottom-line profitability.
- \* Self starter with out-going personality who needs no supervision
- \* Computer literate ( word processing/spread sheets/database programs)

**ACHIEVEMENTS:**

- \* Highly successful in client/customer satisfaction
- \* Maintained excellent business relationships with clients, customers, employees and related companies.
- \* Experienced hands on related jobs

**WORK HISTORY:**

**- Auctioneer/Realtor**

Selling high end real estate at Auction in the Gulf Coast Florida area. Assist customers in the offering of property at auction. Meet clients and evaluate their property to be offered at auction, market, advertise, arrange for auction, bid call, ring, arrange for contracts, closings, all aspects of auction. Arrange for all aspects of the auction method and other needed detail information.

06/05-06-07

**Southern Auction Service-Owner**

Auction firm in North West Florida specializing in real estate and personal property at auction. Meet with clients to evaluate their property to be offered at auction. Meet with real estate agents, bankers, mortgage firms, government officials offering to sell at auction. Arrange for marketing/advertising of auctions. Conduct live auctions.

09/00-05/05

**Turnkey Realty-Southern Auction Service-Co-Owner/General Manager**

Major auction firm central Florida, offering pre-construction homes, condominiums, residential property, acreage, all types of property at auction. Offering personal property, estates, household items, farm & construction equipment at auction. Responsible for all sales personal and employees. Hire, train and assist all sales personal in the success of sales center in obtaining production goals.

11/97-08/00

**Southern Realty - Owner/Real Estate Broker**

Meet, greet clients in model home environment. Assit with the choice of lot, model, interior/exterior of home, financing, closing of home. Promotes real estate services and sales in order to obtain sales center. Studies property listings to become familiar with properties for sale. Accompany prospects to property sites, quotes purchase price, describes features, and discusses conditions of sale or lease. Draws up real estate contracts, such as deeds, leases and mortgages. Negotiate loans or financing. Manage day to day operation of real estate office in the listing, selling, lease, management of associated real estate. View property for listing, selling, leasing for clients, customers.

03/87 - 08/97

**Professional Auction Realty- Albany, GA.-Auctioneer/Real Estate Broker/Owner**

Major real estate firm specializing in the listing, selling, managing, auction of large tracts of rural property. Contact sellers owning large tracts of farm land, timber land, hunting tracts, recreational tracts, plantations to list and offer to sell property. Assist in the appraisal, value and method of marketing property for the highest dollar value to seller. Assist Farm Credit, Banks, Insurance firms, mortgage company in estimating property value and best marketing to sell property. Provide plats, topography views, legal descriptions, crop or timber values. Show property to potential buyers, preview property for amenities. Write listing agreements, purchase agreements, addendum's, draw up Agreements, crop, timber, and hunting leases.

01/95-06/95

\* **Montgomery Auto Auction- Co-owner - Montgomery, AL**

03/93-12/94

\* **Albany Auto Auction -General Manager- Albany, GA.**

Previous:

**Regional Director of Specialized Telecommunication Sales -  
Western Union Corporation -Managed 173 employees, 9 Southern States**

**EDUCATION:** \* LLB - LaSalle Law University - Chicago, IL.

- \* Bachelor of Business Administration - University of Tampa
- \* Associate Engineer Telecommunication - DeVry Technical Institute
- \* Attended Albany Jr. College
- \* Licensed Real Estate Broker - Georgia
- \* Obtained Certified Residential Appraiser - Georgia
- \* Licensed Real Estate Sales - Florida
- \* Licensed Auctioneer - Florida
- \* Real Estate Sales - Alabama - Inactive
- \* Various homes, sales seminar
- \* Various real estate sales seminar

**REFERENCES:** Upon Request

**SALARY:**

Salary or Draw plus bonus and/or commission

# INTRODUCING

## QUINTON SMITH

- \* TOP SALESMAN - 2003 - 2001 - 2000 - 1998 - 1996  
Major Builder & Real Estate Firm
- \* TOP PRODUCER - 2003 - 2001 - 2000 - 1998 - 1996  
Major Builder & Real Estate Firm
- \* ROOKIE OF THE YEAR - 1996  
Major Builder & Real Estate Firm
- \* REAL ESTATE SALES - DEVELOPER/BUILDER - OVER TWENTY YEARS
- \* SOLD OVER 120 HOMES IN ONE WEEK
- \* SOLD THE LARGEST TRACT OF LAND - HIGHEST PRICE IN GEORGIA
- \* NOMINATED WHO'S WHO REAL ESTATE - 2007-2008
- \* METROPOLITAN WHO'S WHO IN CONSTRUCTION 2005-2006
- \* NOMINATED WHO'S WHO SOUTH & SOUTHEAST - 2003 - 2004
- \* NOMINATED WHO'S WHO SOUTH & SOUTHEAST - 1997-1998
- \* WHO'S WHO SOUTH SOUTHEAST - 1990-1991
- \* WHO'S WHO SOUTH & SOUTHEAST - 1980-1981
- \* WRITER- PUBLISHED - AUCTIONS, ANTIQUES, REAL ESTATE, COLLECTABLES
- \* MAJOR SALES AWARDS - VARIES MAJOR INDUSTRIES
- \* REGIONAL DIRECTOR SALES - MAJOR INDUSTRY
- \* AREA TRAINING SPECIALIST - SALES & TECHNICAL - MAJOR INDUSTRY
- \* SPEAKER OF THE YEAR - SALES & MOTIVATION  
Toastmaster International
- \* TIGER AWARD - NEW SALES PRODUCT AWARD- Major Company
- \* MEMBER MOOSE \* MEMBER VFW \* MEMBER AMERICAN LEGION
- \* MEMBER SHRINE \* MEMBER SCOTTISH RITES 32 DEGREE
- \* MEMBER MASONIC LODGE
- \* LL.B. LASALLE LAW UNIVERSITY - Chicago, Il.
- \* BACHELOR OF SCIENCE - BUSINESS ADMINISTRATION-U. of Tampa
- \* BACHELOR OF SCIENCE - REAL ESTATE- UAR
- \* ASSOCIATE ENGINEER - TELECOMMUNICATIONS- DeVry Technical Institute
- \* COMPLETED FLORIDA GENERAL CONTRACTOR SCHOOL
- \* GENERAL CONTRACTOR LICENSES -FL. APPLICATION
- \* GEORGIA LICENSED BUILDER
- \* CERTIFIED RESIDENTIAL APPRAISER - GA.
- \* LICENSED REAL ESTATE SALES - FLORIDA
- \* LICENSED REAL ESTATE BROKER - GEORGIA
- \* LICENSED REAL ESTATE SALES -ALABAMA
- \* LICENSED AUCTIONEER - FL.



**Southern Auction Service**  
**Col. Quinton Smith**

*Real Estate Sales FL. & GA.*  
*Auctioneer/Broker*



## Experience

With the kind of know-how that comes from 30 years of successfully Auctioneering and selling real estate, Quinton Can handle the most complicated real estate transactions. Combined with his insight into the local community, Quinton has become the local expert at putting together smooth, trouble-free transactions-and lots of 'em!



**Quinton Smith**

## COMMITMENT

To do an even better job for his clients and to stay ahead in a very competitive field, Quinton continues to take sales and real estate seminars and classes. He has Real Estate licenses for other states, including being a Certified Appraiser.

## HARD WORK

Quinton is a dynamo, working full time (and then some) at his profession. With the help of his associates, who know where Quinton is at all times, clients can reach Quinton easily and count on a quick and helpful response.

## ATTITUDE

You'll be hard-pressed to find an Auctioneer, agent with more enthusiasm or a more positive attitude than Quinton Smith. Quinton loves what he does - that's his secret!

## INTEGRITY

"People are trusting me with their their most valuable asset. It's a responsibility I take very seriously. I give 1000 percent because I know that their success is my success."

## RESULTS

Ranked #1 for the past several years and consistently a best seller in the area, Quinton has been very successful in selling at auction. Now, past results may not be the only measure of success, but when it comes time to sell your real estate, can you think of anything better to go by?



# Thomas (Tommy) Smith

---

**Objective** To work diligently to make Georgia the most desirable State in the United States of America in which to live and do business.

**Political Experience** Served one and a half terms on the City Council of Forest Park, Georgia 2013-2017. Ran for Georgia Senate District 34 in 2018.

**Employment**

**Border Equipment** Conley, GA  
Heavy Rental Delivery Driver  
Responsible for pick-up and delivery of heavy equipment. Completing paperwork associated with rental agreements. Using good judgment in the everyday operation of heavy equipment in the Metro Atlanta Area traffic.

**J&J Exclusive** Lake City, Ga  
**Transport Driver**  
Responsible for the safe transport of Carmax automobiles from point A to point B.

**Cowin Equipment** Mableton, Ga  
Heavy Rental Delivery Driver  
Responsible for pick-up and delivery of heavy equipment. Completing paperwork associated with rental agreements. Using good judgment in the everyday operation of heavy equipment in the Metro Atlanta Area traffic.

**Southeastern Freight Lines** Conley, Ga  
P&D Driver/Line Haul Driver  
Responsible for pickup and delivery of freight. Completing paperwork associated with shipping and receiving. Using good judgment in the everyday operation of heavy equipment in the Metro Atlanta Area traffic.

**Education**

**University of Georgia** Tifton, Georgia  
Carl Vinson Government Studies

**Atlanta Area Technical College** Atlanta, Georgia  
Front End Alignment

- Certificate of completion.

**Forest Park High School** Forest Park, Georgia

- Diploma

**Summary of qualifications** Although I might not seem like an obvious choice to fill the unexpired term of Senator Isakson there would be no one more dedicated or diligent in the commitment to make the decisions that would be best for all of the Citizens of Georgia and the United States of America as a whole. The common sense approach from a non-career politician would be a definite asset in the Senate right now.

**Professional memberships**

- Clayton County Republican Party
- Vice Chair District 5 Republican Party
- General Motors Certified Technician
- CDL Driver's License
- NHRA Super Gas Driver's License
- Georgia Motorsports Hall of Fame



Law Office of  
**VINCENT D. SOWERBY, P.C.**  
Attorney at Law

September 27, 2019

**CAREER:**

33 years general trial practice in Brunswick, Georgia, the last 23 of which have been self-employed as a sole practitioner, the first 10 of which I was the associate for Joseph H. Ferrier in Brunswick. I have had only these two jobs since graduating law school, with no gaps in my work history. My area of practice is general civil litigation, from medical negligence to domestic relations.

**EDUCATION:**

- Juris Doctor, University of Georgia School of Law, Athens, Georgia 1986
- Bachelor of Arts in history, Duke University, Durham, North Carolina 1983
- Junior year abroad at Albert Ludwigs Universität, Freiburg im Breisgau, West Germany, 1981-1982
- High School Diploma, Pace Academy, Atlanta, Georgia 1979.

**SKILLS:**

- All phases of litigation.
- Successful solo practice, both with and without a secretary.
- Writes well, learns rapidly, high aptitude for all subjects, computer literate, independent, self sufficient, will follow instructions.
- Difficult to intimidate.

**POLITICAL EXPERIENCE:**

None, other than running for election for Glynn County State Court judge in 2012.

**POLITICAL POSITIONS:**

- Republican, Smaller federal government, Return power to States (especially with regard to education, abortion, social transformation, etc.), Avoid war, Secure borders, Balance budget, I usually agree with Pat Buchanan's columns.

**PERSONAL:**

Age 58. Divorced, one child, age 20, Home is on St. Simons Island. Hobbies are offshore fishing and scuba diving. Willing to relocate.

[Resume\_1] ✎

# WILLIAM VARGO



## SUMMARY

## SKILLS

- Inventory oversight
- Material prepping
- Measurements
- Oral and written communication
- Welding equipment
- Job inspections
- Mechanics
- Customer assistance
- Hand assembly
- Task delegation
- Inventory control
- Landscaping and groundskeeping
- Dispatching
- Vendor relations
- Vehicle operation
- Arbitration and litigation
- Product identification
- Issue resolution
- Staff supervision
- Cleaning and sanitizing
- Loading and unloading
- Documentation and reporting
- Sorting and delivery
- Recordkeeping and reporting
- Emergency response
- Performance monitoring
- Quality assurance controls
- Sales techniques
- Regulatory filings and compliance
- Strategic planning
- Inspections
- Financial leadership
- Revenue growth
- Operations oversight
- Marketing expertise
- Policy development
- Supply ordering
- Heavy equipment operation
- Appointment scheduling
- Individual instruction
- Report generation
- Commercial servicing
- Troubleshooting
- Relationship Building
- Multidisciplinary team collaboration
- Business operations
- Commercial equipment operations
- Land use approval process
- Coupling and uncoupling
- Sales strategies
- Leasing and sales
- Task delegation and prioritization
- Inventory management
- Maintenance and repair
- Training and development
- Recruiting and Hiring

TEMPLATE

FORMATTING

SAVE & NEXT





- Cost reduction options
- Materials handling and transport
- Vital sign assessment
- Contract negotiation/review/drafting
- New account development
- Advertising strategies
- Team management
- Employee supervision
- Quality control management
- Payroll and budgeting
- DOT compliance
- Social media management
- Business growth and retention
- Communications
- System diagnostics

## EXPERIENCE

Farmer Retired / Self Employed - Eatonton, GA

01/196

- Purchased supplies, including seeds and fertilizer.
- Drove trucks, tractors and harvesting farm equipment.
- Performed first aid and treated personnel wounds caused by sharp tools and equipment immediate reduced incidences of infection.
- Kept financial records up to date.
- Maintained and repaired farming equipment to provide consistent usability, prime operational conditions alleviate downtime.
- Cultivated and supported wide variety of crops such as fruit trees and vegetable plants by implementing irrigation systems and using drip irrigation.
- Checked fields for rocks or other obstacles to prepare land for tilling and physical preparation for seed planting.
- Oversaw selection and purchase of routine supplies and special equipment purchases as part of \$ yearly budget.
- Inspected all and equipment structures regularly to identify maintenance needs and coordinate skill
- Protected environmental areas, team members and consumers from harm by closely monitoring chemical applications and production techniques.
- Demonstrated working techniques, practices and optimal safety behaviors to workers, maximizing performance and reducing wasteful processes.
- Protected operational interests by inspecting crops every month to determine maturity, detect disease isolate insect infestations.
- Monitored weather conditions and adjusted strategies accordingly to avoid losses.
- Directed efficient crop production to maximize resource utilization and consistently meet schedule and financial demands.
- Installed rock gardens, ponds and irrigation systems in accordance with client specifications.
- Mowed and edged lawns and flowerbeds using all types of mowing equipment and gardening equipment.
- Delineated wetland and stream management zones.
- Tracked production costs
- Operated motorized vehicles and equipment such as semi trucks, tractors and harvest equipment
- Scheduled harvests based on weather conditions and market demands.
- Installed retaining walls, fences and planters.
- Arranged shrubs, trees and flowers to create particular landscape effects.
- Acted as liaison between departments and all outside companies, boards and committees.

TEMPLATE Mixed and applied fertilizers, herbicides and insecticides onto grass, shrubs and trees. Planted seeds, bulbs, grafted covers and trees.

- Revitalized business plans and realigned company objectives to increase overall profits.
- Prepared, negotiated and executed marketing and service level agreements with clients while achieving 100% client retention rate.
- Grew business profits by streamlining processes and trimming unnecessary positions.
- Brought in more than \$500,000 in new business over 2 years.
- Formulated and launched marketing and promotional campaigns to maximize profits.
- Sustained over \$500,000 in annual sales for 10 years.
- Hired, trained and mentored 12 staff members to maximize productivity.
- Developed and monitored internal control systems.
- Grew sales from \$50,000 to \$750,000 and staff from 2 employees to 12 within 1 year.
- Drove revenue up by 500% by cultivating successful client relations.
- Managed company key accounts to promote ongoing project profitability and superior customer satisfaction.
- Led startup and opening of Trucking business and provided business development, creation of operating procedures and workflow planning.
- Implemented strategic offerings to enhance company's suite of products and services.
- Expanded new businesses by developing effective sales, advertising and marketing campaigns.
- Provided organizational leadership and collaborated with executive partners to establish long-term strategies and company policies.
- Generated monthly performance metrics and analytical reports and reviewed and communicated results to clients.
- Monitored industry trends and introduced new services to update marketing strategies.
- Executed on-time, under-budget project management to adhere to project road map.
- Administered day-to-day operations, including accounting and budget management, business development, performance metrics and customer service.
- Optimized supply chain to reduce materials costs and improve distribution.
- Increased company revenue by \$500,000 within first year.
- Oversaw technological improvements, successfully reducing waste and eliminating business bottlenecks.
- Monitored business trend forecasts and adjusted budgets and operational plans to maximize growth opportunities.
- Directed and oversaw capital improvement projects.
- Improved profitability by accurately maintaining P&L to meet prime fiscal responsibility.
- Increased organization's exposure to Trucking industry to grow sales profitability.
- Cultivated and maintained strong industry relationships and customer partnerships to capitalize on opportunities and maximize business success.
- Eliminated debt by accurately forecasting and directing effective contract management and financial planning.
- Directed Safety department.
- Directed Human Resources hiring, training and firing of all employees.
- Managed Maintenance Department and the care of all company equipment.
- Delivered truckloads when needed.
- Managed several truck/trailer units and drivers in a "Just in time Delivery operation" for Ford Motor Company, Lorain, Ohio. 1987-2000

TEMPLATE Directed and assisted with set-up and break down of auction by placing signage, preparing bid cards on day of event.

- Collaborated with auctioneers and staff to stage auction items and prepare audio equipment. ^
- Prepared marketing and advertising campaigns to attract high net-worth buyers and collectors.
- Attended tradeshow and events to meet potential clients and promote auction business.
- Generated auction donations by publicizing auction cause and securing donations by contacting pc auction donors.
- Updated clients throughout auction preparation and process to involve in decision-making.
- Suggested most appropriate and lucrative auction type such as live auction or internet auction.
- Communicated with prospects to present auction services, answer questions and expand client ba
- Created and implemented store displays, promoting sales and growth.
- Identified customer needs to deliver relevant product solutions and promotions that met target budg
- Generated sales by prospecting leads, cold calling and negotiating advantageous deals.
- Capitalized on growth and expanded opportunities by maintaining thorough and current knowledge products, competitive offerings and market developments.
- Improved profitability and developed pipeline leveraging multiple marketing channels and sales str
- Demonstrated products at customer locations, answering questions and redirecting objections to cl
- Implemented consultative sales techniques to generate revenues and exceed sales targets.
- Prepared and processed contracts and order forms for new and existing customers.
- Forecasted sales for different accounts and managed inventory to ensure sufficient products at eac
- Assisted customers during selection process and helped choose perfect products to meet individua
- Cultivated professional client relationships by asking appropriate questions, identifying needs and i insightful information regarding products.
- Met with store managers to discuss product needs, accomplish sales goals and facilitate sales gro
- Grew repeat business by providing superior customer service.
- Answered customers' questions and addressed problems and complaints in person and via phone.
- Developed and implemented restructuring solutions, training programs and process improvement i boost performance
- Built strong, professional relationships through identification of client needs, which increased overa and opportunities.
- Networked to build client base and promote products to new and existing clients.
- Cross-sold additional products and services to purchasing customers.
- Established and serviced accounts in assigned territory.
- Ensured effective customer communication to maintain customer satisfaction and loyalty.
- Presented professional appearance at all times and assisted with product placement and visual merchandising tasks.
- Built new business partnerships
- Promoted memorable shopping experiences resulting in increased customer retention and loyalty.
- Addressed marketing needs of customers by creating and designing ads that promoted goods and advertisers.
- Collaborated with retailers to strengthen product exposure with optimal locations, shelf positions ar
- Consulted with long-term, new and prospective customers to understand needs and propose ideal
- Coordinated various duties, including schedules, payments and allocations between multiple stake while effectively monitoring over 1500 customer accounts.
- Negotiated and closed deals with minimal oversight.
- Landed new customer accounts through effective customer service and powerful cold-calling script
- Implemented sales plans for classified newspaper advertising by identifying and calling on prospec
- Provided customers with recommendations to promote brand effectiveness and product benefits. v

TEMPLATE

Model 7

FORMATTING

SAVE & NEXT

<

>

- Developed relationships with customers and presented promotions that increased shelf space, sales & profit.
- Educated customers on suitable products and services depending on age, needs and inventories to increase sales.
- Increased number of return customers through effective problem solving and conflict resolution.
- Implemented professional sales presentations to creatively communicate product quality and make comparisons.
- Reached out to customers to set up appointments, check on satisfaction and suggest additional offerings.
- Introduced customers to new offerings and updated accounts.
- Cultivated long-term relationships with clients to accurately quote prices and terms that achieved company objectives.
- Improved advertising initiative outreach and building engagement by executing social media and direct marketing campaigns.
- Raised productivity by working closely with cross-functional team members.

**EMT-Basic / Allen Township Volunteer Fire Dept - Williston, OH**

01/198

- Conducted equipment inspections and vehicle checks in adherence with required maintenance schedule.
- Provided direct patient care, including stabilizing patients and determining course of action based on assessment.
- Remained level-headed and proactive during emergency situations.
- Transported patients from accident scenes to hospitals in emergency vehicles.
- Evaluated patients' medical status and monitored vital signs during transit.
- Assessed emergency situations and prioritized medical care for patients.
- Managed care in field and in-transit, including performing standard testing and administering necessary medication.
- Monitored patients from scene to hospital transfer while conducting in-transit care.
- Operated ambulance to and from scenes and emergency facilities, responding to dispatch calls for medical assistance.
- Completed emergency treatment procedures to stabilize individuals for transport.
- Immobilized patients for transport using backboard or other spinal mobilization.
- Collaborated with team members and other first responders, ensuring consistent communication to ensure order and efficient care delivery.
- Delivered first aid or life support care to sick or injured individuals in pre-hospital settings.
- Demonstrated dedication to providing quality care through continued training and education.
- Assessed scenes and prioritized care according to severity of injury or illness.
- Documented all patient information, including condition or injury, treatment and medication administered.
- Developed strong rapport with other medical professionals to foster quality and efficient patient care.
- Delivered exemplary customer service and support by remaining poised in most stressful situations.
- Explained each step of treatment to conscious patients to reduce fear and invoke calm.
- Observed educators in classroom and described methods to improve instructional techniques.
- Responded quickly to medical emergencies to promote best possible health outcomes.
- Treated patients suffering from variety of illnesses and ailments, including heart attacks, strokes, motor vehicle accident injuries and illness.
- Developed exceptional attendance record with special attention to punctuality and preparation to work on arrival.

- Patrolled previously burned areas after fire containment to locate and eliminate dangerous hot spots.
- Rescued victims trapped by fires and rendered first aid.
- Answered emergency situations quickly and assessed conditions to contain fires, assist victims and prevent escalation.
- Located hydrants and operated pumps at proper pressure to evaluate adequacy of water system and availability of water supply.
- Used firefighting and rescue equipment and tools to assist in rescue operations.
- Tested and inspected tools, equipment and gear to maintain readiness for different fire scenarios.
- Assessed nature and extent of fire, condition of buildings, danger to adjacent buildings and water status to determine crew or company requirements.
- Inspected schools, theaters, offices and various other buildings to check for proper fire precautions measures.
- Trained continuously to maintain required physical fitness for demanding work.
- Stayed in close contact with dispatchers to obtain and relay current information about fire status, staff and personnel.
- Ensured that hoses were laid out and properly connected to fire hydrants for fire suppression.
- Met with members of the community to provide information on ways to prevent fires and to offer fire safety tips.
- Handled routine custodial maintenance of fire department equipment to maintain equipment, including breathing, resuscitation and apparatus equipment.
- Rescued fire victims and administered emergency medical aid.
- Responded to over 100 emergency incidents per year and used systematic search and rescue procedures and location and excavation devices to safely locate and evacuate victims.
- Operated pumps connected to high-pressure hoses.
- Responded to medical emergencies, alarms and bomb threats within approximately 8 minutes of call.
- Planned, developed, implemented and monitored fire safety plans that addressed specific fire and life safety systems.
- Checked all equipment, including hoses and breathing masks after fire calls to determine proper function.
- Conducted and planned periodic fire safety inspections to identify unsafe conditions.
- Extinguished flames and embers to suppress fires, using shovels and engine- or hand-driven water pumps.
- Responded to scenes of accidents or acute illness for which emergency medical care has been requested.
- Responded directly to approximately 150 emergency situations in a year.
- Responded to fire alarms and used job-specific equipment, including operating pumps, aerial ladders and auxiliary equipment.
- Revised and maintained all equipment and test logs.
- Promptly responded to incidents and demobilized pertinent equipment, including water tenders and engines.
- Provided emergency treatment and medical care to people injured in accidents and fires.
- Performed inspections of all facilities, equipment, and personnel.
- Conducted search and rescue operations and quickly analyzed all medical emergencies as well as administered first aid to injured persons.
- Performed fundamental firefighter and driver duties when required.
- Drove and operated an ambulance or other apparatus as assigned and operated as a member of the engine or medic truck company.



- Informed and educated the public about fire prevention.
- Cleaned, serviced and maintained fire apparatus in condition of readiness and performed general maintenance work in upkeep of fire department property.
- Laid hose lines, operated nozzles, pumps, and hydrants and utilized fire extinguishers and operate hydraulic, pneumatic, manual and power tools.
- Maintained tools and fire vehicles to ensure rapid response capability.
- Transferred, lifted and moved patients while employing appropriate safety and lifting techniques.
- Attended trainings to maintain wealth of knowledge in firefighting techniques and suppression metth enabling quick decision making during actual emergencies.

**Welder Fabricator / American Shipyard - Toledo, OH**

01/197

- Maintained workplace equipment and inspected it daily for damage.
- Inspected each completed project to make sure that it met all blueprint specifications
- Observed the approved process for assembly.
- Calculated whole numbers, decimals and fractions using simple math.
- Customized techniques for the requirements of each item.
- Operated equipment and welding tools safely by following manufacturer instructions.
- Kept tidy work areas and checked equipment regularly.
- Read and interpreted schematics to create accurate products.
- Performed duties while adhering to workplace protocols and safety rules.
- Used mathematical abilities to measure distances and determine materials needed.
- Uncovered issues and addressed immediately with Foreman to resolve.
- Built parts using MIG and TIG welding techniques.
- Observed safe work practices and procedures as instituted by the company.
- Transported machinery using forklifts, cranes and hoists.
- Created safety guards, angle iron and square tubing.
- Used mig and tig welding techniques to fabricate ship and tube chassis.
- Maximized shop organization and equipment lifespan by maintaining equipment.
- Scraped off excess spatter and other materials using portable grinders and arc-cutting equipment.
- Monitored fitting, burning and welding processes to avoid overheating parts, warping, shrinking, dis expansion of materials.
- Inspected and repaired components to implement corrective action.
- Adjusted gas flow and pressure to create and maintain desired flames.
- Removed loose materials and thick scale, slag or rust to prepare material surfaces for welding.
- Inspected grooves, angles and gap allowances with micrometer, caliper and precision measuring it
- Applied knowledge of metallurgy, geometry and welding techniques to determine optimal welding s
- Prevented distortion of parts by monitoring fitting, burning and welding processes.
- Set up equipment and welded parts according to welding chart specifications and type.
- Improved project completion time by multi-tasking on heavy equipment such as forklifts.
- Improved project completion time by multitasking on heavy equipment such as forklifts.
- Positioned and clamped workpieces together and properly assembled in jigs and fixtures.
- Sustained safety protocols and ensured proper, cost-effective and accurate handling of equipment materials.
- Obtained desired configurations by clamping and tack-welding components.

TEMPLATE Maximized shop organization by maintaining equipment length by efficiently cleaning floor and machinery. Setup and operated welding equipment to complete all welding projects on time

- Combined welding techniques, knowledge of metallurgy and engineering requirements to produce work.

**Chassis Mechanic / Double B Farms - Eatonton, GA**

12/201

Design and build chassis for drag race cars and pulling tractors.

Advertise this business,do quotes, do all aspects of designing ,fabricating and assembling various styles chassis and roll cages for competition tractors and drag cars.

I have built over 20 highly competitive NTPA pulling tractors that went to several states since starting to b them.Some are seen on TV.Some have won State and National championships.

I build and design them from scratch.From a pile of tubing to a turn key tractor,I can do it all. This is a hot

- Inspected each completed project to make sure that it met all blueprint specifications
- Set up and operated production equipment according to daily work orders and safety procedures.
- Transported machinery using forklifts, cranes and hoists.
- Operated equipment and welding tools safely by following manufacturer instructions.
- Observed the approved process for assembly.
- Maintained workplace equipment and inspected it daily for damage.
- Prepared and filed financial statements such as balance sheets and income statements.
- Delivered exemplary customer service and support by remaining poised in most stressful situations
- Protected company reputation and built loyal client base by working relentlessly to resolve problem improve customer satisfaction.
- Received shipments and signed off on packages, documenting all incoming items in sys
- Processed customer payments using cash, checks, credit and debit cards and returned proper bills
- Used troubleshooting methods to identify issues with mechanical tools.
- Identified appropriate solutions to minimize issues and quickly solve problems.
- Replenished items running low in customer inventories by quickly shipping new orders.
- Returned phone messages and emails within 8 hrs and responded to complaints before issues esc
- Created communication strategies to meet client objectives.
- Tracked all leads using internet and followed up with interested parties within 8 hrs.
- Followed industry standards and manufacturer instructions to calibrate measurement tools.
- Developed long-term partnerships with lucrative business customers by promptly addressing areas concern.
- Responded quickly to customer concerns and complaints.
- Reviewed blueprints, drawings and other specifications to fully understand project expectations.
- Researched items at other locations to find products requested by shoppers.
- Delivered an exceptional level of service to each customer by listening to concerns and answering
- Processed payments and returned receipts, cash, coin and payment cards to customers.
- Warmly greeted patrons upon entrance to store and offered assistance with finding needed items.

## EDUCATION AND TRAINING

Penta County Joint Vocational School - Perrysburg, OH  
High School Diploma

TEMPLATE

Modern 7 v

FORMATTING

v

SAVE & NEXT

<

>

# ZACHERY GILLESPIE

---

## SUMMARY

Insurance claims professional versed in all aspects of personal lines property and casualty claims. Self managed, results-oriented, and high-energy professional with a talent for leading by example and inspiring peak performance. Over seven years of property insurance claims experience and repeated success in time management, exceeding performance targets, and promoting team engagement. Ability to establish and maintain strong alliances; lead and motivate teams; drive projects to successful completion; convey technical requirements/data; and exceed customer expectations.

## EDUCATION

**The University of Georgia**, Terry College of Business Athens, GA  
*Bachelor of Business Administration in Management, Cum Laude Graduate* May 2008

- Overall GPA 3.6/4.0
- HOPE Scholarship Recipient; Dean's List; Presidential Scholar

## PROFESSIONAL EXPERIENCE

**Nationwide Insurance** Duluth, GA

*Claims Field Specialist II – Personal Lines Property* November 2011-Present  
Analyze claims to determine extent of company's liability, make approval or denial decisions and negotiate settlements with claimants in accordance with policy provisions. Collaborate with insurance agents and claimants to settle claims and investigate questionable issues.

### Outcomes:

- Provided optimum service to policyholders, negotiated fair settlements, and identified fraudulent claims.
- Built working relationships with vendors to build rapport, exceed customer service expectations, and resolve claims
- Actively interviewed new hire candidates with supervisor and assisted in review of candidates for open positions
- Assisted with team communications and training to promote and improve cohesiveness and goals
- Maintained superior metrics in customer surveys, file quality rating, on-site settlements and payment, customer contact and follow up, and days to first payment exceeding department goals
- Selected by supervisor to assist with file closures; resolve complex claims issues for colleagues; participate in quality-control audits/ride along; and review monthly claim reports

**Travelers Insurance** Alpharetta, GA

*Outside Claims Representative – Personal and Commercial Lines Property* October 2008-November 2011  
Analyze claims to determine extent of company's liability, make approval or denial decisions and negotiate settlements with claimants in accordance with policy provisions. Analyzed and determined completeness and validity of claims. Assisted policyholders in a settlement of claims.

### Outcomes:

- Respected leader that trained new hires in estimating skills, time management, and product quality
- Self managed professional working in field to investigate claims and determine cause and extent of damages
- Developed a strong understanding of insurance policies and legal issues through in-depth, multi-week claims training and claims experience
- Actively developed and maintained claims documentation program to ensure file quality, work efficiency, and better organization
- Provided optimum service to policyholders while maintaining superior metrics
- Served as stand-in unit manager for daily operations and oversight of claims work and reports
- Managed Technical Specialist claims to resolution in excess of \$100,000

**Blockbuster Video, Inc.** Monroe, GA

*Team Leader* June 2004-March 2006; January 2007-September 2007  
Handle customer inquiries, complaints, and service requests. Assisted customers in selecting merchandise, answering questions, and quickly resolving concerns. Participated in ongoing training. Coached and mentored new associates in sales strategies and internal policies.

### Outcomes:

- Coordinated with supervisor to run efficient and productive day to day activities
- Motivated employees to reach sales goals and recognized daily goal achievements
- Assumed responsibility of opening and closing operations for the store and assigning employee work roles
- Strengthened customer relations by being empathetic to the customer's needs and resolving problems efficiently
- Managed front-end operations to ensure friendly and efficient transactions at checkout

## HONORS / ACTIVITIES

- Nationwide Emerging Leaders Program (2014), Bravo Award Recipient
- Travelers 100% Claims Quality Award, Subrogation Recovery Award, 2010 In-Sync Award Nominee
- Bethlehem Baptist Church, *Member, Deacon, Middle School Youth Small Group Leader*; New Testament Baptist Church, *Youth Activity Coordinator, Children's Kindergarten Teacher, Community Work*
- Dixie Children's Baseball League, *Head Coach*

References Available Upon Request